{ "version": "2.2", "instance": { "ea0202318-s1a3_abvcbio.htm": { "nsprefix": "abvc", "nsuri": "http://www.abvcpharma.com/20231231", "dts": { "schema": { "local": [ "abvc-20231231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd" ] }, "calculationLink": { "local": [ "abvc-20231231_cal.xml" ] }, "definitionLink": { "local": [ "abvc-20231231_def.xml" ] }, "labelLink": { "local": [ "abvc-20231231_lab.xml" ] }, "presentationLink": { "local": [ "abvc-20231231_pre.xml" ] }, "inline": { "local": [ "ea0202318-s1a3_abvcbio.htm" ] } }, "keyStandard": 350, "keyCustom": 72, "axisStandard": 16, "axisCustom": 0, "memberStandard": 26, "memberCustom": 44, "hidden": { "total": 174, "http://fasb.org/us-gaap/2023": 140, "http://www.abvcpharma.com/20231231": 31, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 272, "entityCount": 1, "segmentCount": 88, "elementCount": 645, "unitCount": 6, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 876, "http://xbrl.sec.gov/dei/2023": 9, "http://fasb.org/srt/2023": 2 }, "report": { "R1": { "role": "http://www.abvcpharma.com/role/DocumentAndEntityInformation", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "longName": "001 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:AccountsReceivableNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R3": { "role": "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)", "shortName": "Consolidated Balance Sheets (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "usdPershares", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R4": { "role": "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "longName": "003 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:Revenues", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R5": { "role": "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement_Parentheticals", "longName": "004 - Statement - Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "shortName": "Consolidated Statements of Operations and Comprehensive Loss (Parentheticals)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "5", "firstAnchor": null, "uniqueAnchor": null }, "R6": { "role": "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "longName": "005 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c5", "name": "abvc:InventoryAllowanceForValuationLosses", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R7": { "role": "http://www.abvcpharma.com/role/ShareholdersEquityType2or3", "longName": "006 - Statement - Consolidated Statements of Stockholders\u2019 Equity (Deficit)", "shortName": "Consolidated Statements of Stockholders\u2019 Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c7", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c7", "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusiness", "longName": "007 - Disclosure - Organization and Description of Business", "shortName": "Organization and Description of Business", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.abvcpharma.com/role/LiquidityandGoingConcern", "longName": "008 - Disclosure - Liquidity and Going Concern", "shortName": "Liquidity and Going Concern", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c0", "name": "abvc:LiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:LiquidityAndGoingConcernTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPolicies", "longName": "009 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.abvcpharma.com/role/CollaborativeAgreements", "longName": "010 - Disclosure - Collaborative Agreements", "shortName": "Collaborative Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.abvcpharma.com/role/PropertyandEquipment", "longName": "011 - Disclosure - Property and Equipment", "shortName": "Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.abvcpharma.com/role/LongTermInvestments", "longName": "012 - Disclosure - Long-Term Investments", "shortName": "Long-Term Investments", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:InvestmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.abvcpharma.com/role/ConvertibleNotesPayable", "longName": "013 - Disclosure - Convertible Notes Payable", "shortName": "Convertible Notes Payable", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.abvcpharma.com/role/AccruedExpensesandOtherCurrentLiabilities", "longName": "014 - Disclosure - Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.abvcpharma.com/role/BankLoans", "longName": "015 - Disclosure - Bank Loans", "shortName": "Bank Loans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.abvcpharma.com/role/RelatedPartiesTransactions", "longName": "016 - Disclosure - Related Parties Transactions", "shortName": "Related Parties Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.abvcpharma.com/role/IncomeTaxes", "longName": "017 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.abvcpharma.com/role/Equity", "longName": "018 - Disclosure - Equity", "shortName": "Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.abvcpharma.com/role/StockOptions", "longName": "019 - Disclosure - Stock Options", "shortName": "Stock Options", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.abvcpharma.com/role/LossPerShare", "longName": "020 - Disclosure - Loss Per Share", "shortName": "Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.abvcpharma.com/role/Lease", "longName": "021 - Disclosure - Lease", "shortName": "Lease", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.abvcpharma.com/role/CommitmentsAndContingencies", "longName": "022 - Disclosure - Commitments And Contingencies", "shortName": "Commitments And Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.abvcpharma.com/role/Acquisition", "longName": "023 - Disclosure - Acquisition", "shortName": "Acquisition", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.abvcpharma.com/role/SubsequentEvents", "longName": "024 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R26": { "role": "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy", "longName": "996000 - Disclosure - Accounting Policies, by Policy (Policies)", "shortName": "Accounting Policies, by Policy (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "26", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R27": { "role": "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesTables", "longName": "996001 - Disclosure - Summary of Significant Accounting Policies (Tables)", "shortName": "Summary of Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c0", "name": "abvc:ScheduleOfPropertySubjectToOrAvailableForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:ScheduleOfPropertySubjectToOrAvailableForCapitalLeaseTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.abvcpharma.com/role/PropertyandEquipmentTables", "longName": "996002 - Disclosure - Property and Equipment (Tables)", "shortName": "Property and Equipment (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.abvcpharma.com/role/LongTermInvestmentsTables", "longName": "996003 - Disclosure - Long-Term Investments (Tables)", "shortName": "Long-Term Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c0", "name": "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.abvcpharma.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "longName": "996004 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.abvcpharma.com/role/BankLoansTables", "longName": "996005 - Disclosure - Bank Loans (Tables)", "shortName": "Bank Loans (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShortTermDebtTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables", "longName": "996006 - Disclosure - Related Parties Transactions (Tables)", "shortName": "Related Parties Transactions (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfRelatedPartyTransactionsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.abvcpharma.com/role/IncomeTaxesTables", "longName": "996007 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.abvcpharma.com/role/StockOptionsTables", "longName": "996008 - Disclosure - Stock Options (Tables)", "shortName": "Stock Options (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.abvcpharma.com/role/LossPerShareTables", "longName": "996009 - Disclosure - Loss Per Share (Tables)", "shortName": "Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.abvcpharma.com/role/LeaseTables", "longName": "996010 - Disclosure - Lease (Tables)", "shortName": "Lease (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.abvcpharma.com/role/AcquisitionTables", "longName": "996011 - Disclosure - Acquisition (Tables)", "shortName": "Acquisition (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails", "longName": "996012 - Disclosure - Organization and Description of Business (Details)", "shortName": "Organization and Description of Business (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c43", "name": "us-gaap:RoyaltyExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c42", "name": "abvc:AggregateOfSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R39": { "role": "http://www.abvcpharma.com/role/LiquidityandGoingConcernDetails", "longName": "996013 - Disclosure - Liquidity and Going Concern (Details)", "shortName": "Liquidity and Going Concern (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c44", "name": "abvc:WorkingCapitalDeficit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "abvc:LiquidityAndGoingConcernTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R40": { "role": "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails", "longName": "996014 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c45", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c45", "name": "us-gaap:StockholdersEquityReverseStockSplit", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R41": { "role": "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable", "longName": "996015 - Disclosure - Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment Under Capital Leases Based on the Following Useful Lives", "shortName": "Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment Under Capital Leases Based on the Following Useful Lives", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c47", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c47", "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R42": { "role": "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "longName": "996016 - Disclosure - Collaborative Agreements (Details)", "shortName": "Collaborative Agreements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c0", "name": "abvc:MilestonePaymentsRoyaltyPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:MilestonePaymentsRoyaltyPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:CollaborativeArrangementDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "longName": "996017 - Disclosure - Property and Equipment (Details)", "shortName": "Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R44": { "role": "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable", "longName": "996018 - Disclosure - Property and Equipment (Details) - Schedule of Property and Equipment", "shortName": "Property and Equipment (Details) - Schedule of Property and Equipment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R45": { "role": "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "longName": "996019 - Disclosure - Long-Term Investments (Details)", "shortName": "Long-Term Investments (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c0", "name": "abvc:PercentageCommonStocksShares", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:PercentageCommonStocksShares", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R46": { "role": "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable", "longName": "996020 - Disclosure - Long-Term Investments (Details) - Schedule of Ownership Percentages of Each Investee", "shortName": "Long-Term Investments (Details) - Schedule of Ownership Percentages of Each Investee", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c98", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c98", "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R47": { "role": "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "longName": "996021 - Disclosure - Long-Term Investments (Details) - Schedule of Extent the Investee Relies", "shortName": "Long-Term Investments (Details) - Schedule of Extent the Investee Relies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c111", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c111", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:InvestmentTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "longName": "996022 - Disclosure - Long-Term Investments (Details) - Schedule of Long-Term Investment", "shortName": "Long-Term Investments (Details) - Schedule of Long-Term Investment", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c1", "name": "abvc:NonmarketableCostMethodInvestmentsNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "abvc:NonmarketableCostMethodInvestmentsNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable", "longName": "996023 - Disclosure - Long-Term Investments (Details) - Schedule of Balance Sheet", "shortName": "Long-Term Investments (Details) - Schedule of Balance Sheet", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c126", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c126", "name": "us-gaap:AssetsCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R50": { "role": "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable", "longName": "996024 - Disclosure - Long-Term Investments (Details) - Schedule of Statement of Operation", "shortName": "Long-Term Investments (Details) - Schedule of Statement of Operation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c130", "name": "us-gaap:GainLossOnSalesOfLoansNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c130", "name": "us-gaap:GainLossOnSalesOfLoansNet", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.abvcpharma.com/role/ScheduleofLossonInvestmentinEquitySecuritiesTable", "longName": "996025 - Disclosure - Long-Term Investments (Details) - Schedule of Loss on Investment in Equity Securities", "shortName": "Long-Term Investments (Details) - Schedule of Loss on Investment in Equity Securities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:IncomeLossFromEquityMethodInvestments", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R52": { "role": "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "longName": "996026 - Disclosure - Convertible Notes Payable (Details)", "shortName": "Convertible Notes Payable (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c141", "name": "abvc:PurchaseWarrantTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:PercentageOfCashPermium", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "us-gaap:DebtDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R53": { "role": "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable", "longName": "996027 - Disclosure - Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities", "shortName": "Accrued Expenses and Other Current Liabilities (Details) - Schedule of Accrued Expenses and Other Current Liabilities", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c1", "name": "abvc:AccruedResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "abvc:AccruedResearchAndDevelopmentExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.abvcpharma.com/role/BankLoansDetails", "longName": "996028 - Disclosure - Bank Loans (Details)", "shortName": "Bank Loans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c180", "name": "us-gaap:AccountsPayableInterestBearingInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c170", "name": "us-gaap:OtherShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R55": { "role": "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable", "longName": "996029 - Disclosure - Bank Loans (Details) - Schedule of Short-Term Bank Loan", "shortName": "Bank Loans (Details) - Schedule of Short-Term Bank Loan", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:ShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c153", "name": "us-gaap:ShortTermBorrowings", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:ShortTermDebtTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R56": { "role": "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "longName": "996030 - Disclosure - Related Parties Transactions (Details)", "shortName": "Related Parties Transactions (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c180", "name": "us-gaap:AccountsPayableInterestBearingInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c181", "name": "abvc:WorkingCapitalPercentage", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "span", "p", "td", "tr", "table", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R57": { "role": "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable", "longName": "996031 - Disclosure - Related Parties Transactions (Details) - Schedule of Related Parties of the Company with whom Transactions", "shortName": "Related Parties Transactions (Details) - Schedule of Related Parties of the Company with whom Transactions", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c203", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c203", "name": "us-gaap:RelatedPartyTransactionDescriptionOfTransaction", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable", "longName": "996032 - Disclosure - Related Parties Transactions (Details) - Schedule of Accounts Receivable Due From Related Parties", "shortName": "Related Parties Transactions (Details) - Schedule of Accounts Receivable Due From Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:AccountsAndOtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R59": { "role": "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable", "longName": "996033 - Disclosure - Related Parties Transactions (Details) - Schedule of Revenue Due From Related Parties - Current", "shortName": "Related Parties Transactions (Details) - Schedule of Revenue Due From Related Parties - Current", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c0", "name": "abvc:RevenueFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "abvc:RevenueFromRelatedParty", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "longName": "996034 - Disclosure - Related Parties Transactions (Details) - Schedule of Due From Related Parties - Current", "shortName": "Related Parties Transactions (Details) - Schedule of Due From Related Parties - Current", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c3", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c128", "name": "us-gaap:OtherReceivablesNetCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R61": { "role": "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable", "longName": "996035 - Disclosure - Related Parties Transactions (Details) - Schedule of Due From Related Parties - Non Current", "shortName": "Related Parties Transactions (Details) - Schedule of Due From Related Parties - Non Current", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:OtherReceivableBeforeAllowanceForCreditLossNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:OtherReceivableAllowanceForCreditLossNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R62": { "role": "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable", "longName": "996036 - Disclosure - Related Parties Transactions (Details) - Schedule of Amount Due to Related Parties", "shortName": "Related Parties Transactions (Details) - Schedule of Amount Due to Related Parties", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": { "contextRef": "c123", "name": "us-gaap:OtherLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "unique": true } }, "R63": { "role": "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable", "longName": "996037 - Disclosure - Income Taxes (Details) - Schedule of Income Tax Expense", "shortName": "Income Taxes (Details) - Schedule of Income Tax Expense", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c5", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c5", "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable", "longName": "996038 - Disclosure - Income Taxes (Details) - Schedule of Deferred Tax Assets (Liability)", "shortName": "Income Taxes (Details) - Schedule of Deferred Tax Assets (Liability)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOther", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:DeferredTaxAssetsOther", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.abvcpharma.com/role/EquityDetails", "longName": "996039 - Disclosure - Equity (Details)", "shortName": "Equity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c223", "name": "us-gaap:DeferredOfferingCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c223", "name": "us-gaap:DeferredOfferingCosts", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.abvcpharma.com/role/StockOptionsDetails", "longName": "996040 - Disclosure - Stock Options (Details)", "shortName": "Stock Options (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c251", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c251", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable", "longName": "996041 - Disclosure - Stock Options (Details) - Schedule of Options Issued and Outstanding", "shortName": "Stock Options (Details) - Schedule of Options Issued and Outstanding", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c260", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c260", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.abvcpharma.com/role/ScheduleofFairValueofStockOptionsGrantedTable", "longName": "996042 - Disclosure - Stock Options (Details) - Schedule of Fair Value of Stock Options Granted", "shortName": "Stock Options (Details) - Schedule of Fair Value of Stock Options Granted", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "unitRef": "pure", "xsiNil": "false", "lang": null, "decimals": "4", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R69": { "role": "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable", "longName": "996043 - Disclosure - Loss Per Share (Details) - Schedule of Loss Per Share", "shortName": "Loss Per Share (Details) - Schedule of Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c28", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c28", "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:EarningsPerShareTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R70": { "role": "http://www.abvcpharma.com/role/LeaseDetails", "longName": "996044 - Disclosure - Lease (Details)", "shortName": "Lease (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:LesseeOperatingLeaseRemainingLeaseTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:OperatingLeaseLeaseIncomeTableTextBlock", "span", "p", "us-gaap:LesseeOperatingLeasesTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable", "longName": "996045 - Disclosure - Lease (Details) - Schedule of Operating Leases have Remaining Lease Terms", "shortName": "Lease (Details) - Schedule of Operating Leases have Remaining Lease Terms", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true }, "uniqueAnchor": null }, "R72": { "role": "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable", "longName": "996046 - Disclosure - Lease (Details) - Schedule of Company\u2019s Lease Expenses", "shortName": "Lease (Details) - Schedule of Company\u2019s Lease Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c0", "name": "us-gaap:OperatingLeaseExpense", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R73": { "role": "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable", "longName": "996047 - Disclosure - Lease (Details) - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases", "shortName": "Lease (Details) - Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c1", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "ix:continuation", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R74": { "role": "http://www.abvcpharma.com/role/AcquisitionDetails", "longName": "996048 - Disclosure - Acquisition (Details)", "shortName": "Acquisition (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c263", "name": "abvc:SharesReceived", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c263", "name": "abvc:SharesReceived", "unitRef": "shares", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "span", "p", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R75": { "role": "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable", "longName": "996049 - Disclosure - Acquisition (Details) - Schedule of Acquisition was Accounted for Business Combination", "shortName": "Acquisition (Details) - Schedule of Acquisition was Accounted for Business Combination", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c1", "name": "abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c1", "name": "abvc:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "td", "tr", "table", "ix:continuation", "us-gaap:AssetAcquisitionTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } }, "R76": { "role": "http://www.abvcpharma.com/role/SubsequentEventsDetails", "longName": "996050 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "76", "firstAnchor": { "contextRef": "c264", "name": "us-gaap:DebtInstrumentIssuedPrincipal", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c264", "name": "us-gaap:DebtInstrumentIssuedPrincipal", "unitRef": "usd", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "div", "body", "html" ], "reportCount": 1, "baseRef": "ea0202318-s1a3_abvcbio.htm", "first": true, "unique": true } } }, "tag": { "country_AU": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2023", "localname": "AU", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Australia [Member]", "verboseLabel": "AUSTRALIA", "label": "AUSTRALIA" } } }, "auth_ref": [] }, "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccountsAndOtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsAndOtherReceivablesNetCurrent", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable due from related parties", "label": "Accounts and Other Receivables, Net, Current", "documentation": "Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_AccountsNotesAndLoansReceivableLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsNotesAndLoansReceivableLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts Receivable Due From Related Parties [Line Items", "terseLabel": "Accounts, Notes, Loans and Financing Receivable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccruedExpensesandOtherCurrentLiabilities" ], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r25" ] }, "us-gaap_AccountsPayableInterestBearingInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsPayableInterestBearingInterestRate", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate of loan", "verboseLabel": "Loans bear interest rate", "label": "Accounts Payable, Interest-Bearing, Interest Rate", "documentation": "Reflects the effective interest rate as of the balance sheet date on interest-bearing trade payables." } } }, "auth_ref": [ "r95", "r96", "r97", "r98" ] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable, net", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": [ "r310", "r311" ] }, "us-gaap_AccountsReceivableNoncurrentAccruedInterestWriteoff": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccountsReceivableNoncurrentAccruedInterestWriteoff", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Accounts Receivable, Noncurrent, Accrued Interest, Writeoff", "documentation": "Amount of writeoff of accrued interest on accounts receivable classified as noncurrent recognized by reversing interest income." } } }, "auth_ref": [ "r328" ] }, "abvc_AccountsReceivableRelatedPartiesNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AccountsReceivableRelatedPartiesNet", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable \u2013 related parties, net", "documentation": "Represent the amount of accounts receivable related parties net.", "label": "Accounts Receivable Related Parties Net" } } }, "auth_ref": [] }, "us-gaap_AccruedEmployeeBenefitsCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedEmployeeBenefitsCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee benefits expensed as incurred", "label": "Accrued Employee Benefits", "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them." } } }, "auth_ref": [ "r104" ] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses and other current liabilities", "verboseLabel": "Total", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30" ] }, "abvc_AccruedResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AccruedResearchAndDevelopmentExpense", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued research and development expense", "documentation": "Accrued research and development expense.", "label": "Accrued Research And Development Expense" } } }, "auth_ref": [] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30", "r707" ] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r64", "r220", "r572" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive income", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r42", "r43", "r124", "r227", "r567", "r588", "r589" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r4", "r13", "r43", "r490", "r493", "r526", "r584", "r585", "r757", "r758", "r759", "r768", "r769", "r770" ] }, "abvc_AdditionCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AdditionCashPayment", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Addition cash payment", "documentation": "The amount of addition cash payment.", "label": "Addition Cash Payment" } } }, "auth_ref": [] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r119", "r727", "r849" ] }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r119" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-in Capital", "label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r447", "r448", "r449", "r603", "r768", "r769", "r770", "r821", "r851" ] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation for options granted", "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant issued with convertible notes payable", "label": "Adjustments to Additional Paid in Capital, Warrant Issued", "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants." } } }, "auth_ref": [ "r14", "r66", "r153" ] }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "abvc_AggregateCommonStockShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AggregateCommonStockShares", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate common stock", "documentation": "Aggregate common stock shares.", "label": "Aggregate Common Stock Shares" } } }, "auth_ref": [] }, "abvc_AggregateOfSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AggregateOfSharesIssued", "presentation": [ "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate of shares, issued (in Shares)", "documentation": "Total share amount of aggregate of shares, issued.", "label": "Aggregate Of Shares Issued" } } }, "auth_ref": [] }, "abvc_AgreementPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "AgreementPercentage", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Agreement percentage", "documentation": "Agreement percentage.", "label": "Agreement Percentage" } } }, "auth_ref": [] }, "us-gaap_AllowanceForDoubtfulAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AllowanceForDoubtfulAccountsReceivable", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Allowance for expected credit losses accounts", "label": "Accounts Receivable, Allowance for Credit Loss", "documentation": "Amount of allowance for credit loss on accounts receivable." } } }, "auth_ref": [ "r228", "r314", "r324", "r325", "r327", "r845" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Description", "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r481" ] }, "us-gaap_AssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Acquisition [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetAcquisitionTextBlock", "presentation": [ "http://www.abvcpharma.com/role/Acquisition" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITION", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r820" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of prepaid expenses", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r9", "r62" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r163", "r221", "r254", "r290", "r300", "r304", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r483", "r487", "r499", "r562", "r635", "r727", "r739", "r782", "r783", "r831" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" ], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Assets", "terseLabel": "Current Assets", "label": "Assets, Current", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events." } } }, "auth_ref": [ "r214", "r230", "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r483", "r487", "r499", "r727", "r782", "r783", "r831" ] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsCurrentAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Assets", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "AssetsNoncurrent", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current Assets", "label": "Assets, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r483", "r487", "r499", "r782", "r783", "r831" ] }, "abvc_BHKCoDevelopmentAggreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BHKCoDevelopmentAggreementMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BHK Co Development Agreement [Member]", "label": "BHKCo Development Aggreement Member" } } }, "auth_ref": [] }, "abvc_BHKCoDevelopmentAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BHKCoDevelopmentAgreementMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BHK Co-Development Agreement [Member]", "label": "BHKCo Development Agreement Member" } } }, "auth_ref": [] }, "abvc_BankLoansDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BankLoansDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "label": "Bank Loans (Details) [Table]" } } }, "auth_ref": [] }, "abvc_BarlewHoldingsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BarlewHoldingsLLCMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Barlew Holdings, LLC [Member]", "label": "Barlew Holdings LLCMember" } } }, "auth_ref": [] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "abvc_BearInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BearInterestRateMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bear Interest Rate [Member]", "label": "Bear Interest Rate Member" } } }, "auth_ref": [] }, "abvc_BeneficialConversionFeaturePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BeneficialConversionFeaturePolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Beneficial Conversion Feature", "documentation": "Disclosure of accounting policy for beneficial conversion feature.", "label": "Beneficial Conversion Feature Policy Text Block" } } }, "auth_ref": [] }, "abvc_BioFirstAustraliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstAustraliaMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst (Australia) [Member]", "label": "Bio First Australia Member" } } }, "auth_ref": [] }, "abvc_BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstAustraliaPtyLtdtheBioFirstAustraliaMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst (Australia) Pty Ltd. (the \u201cBioFirst (Australia)\u201d) [Member]", "label": "Bio First Australia Pty Ltdthe Bio First Australia Member" } } }, "auth_ref": [] }, "abvc_BioFirstCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstCorporationMember", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst Corporation [Member]", "verboseLabel": "BioFirst [Member]", "label": "Bio First Corporation Member" } } }, "auth_ref": [] }, "abvc_BioFirstCorporationtheBioFirstMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstCorporationtheBioFirstMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst Corporation (the \"BioFirst\") [Member]", "label": "Bio First Corporationthe Bio First Member" } } }, "auth_ref": [] }, "abvc_BioFirstMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst [Member]", "label": "Bio First Member" } } }, "auth_ref": [] }, "abvc_BioFirstStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioFirstStockPurchaseAgreementMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioFirst Corporation Purchase Agreement [Member]", "label": "Bio First Stock Purchase Agreement Member" } } }, "auth_ref": [] }, "abvc_BioHopeKingCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioHopeKingCorporationMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable", "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable", "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "BioHopeKing Corporation [Member]", "label": "Bio Hope King Corporation Member" } } }, "auth_ref": [] }, "abvc_BioLiteTaiwanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BioLiteTaiwanMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "BioLite Taiwan [Member]", "label": "Bio Lite Taiwan Member" } } }, "auth_ref": [] }, "srt_BoardOfDirectorsChairmanMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "BoardOfDirectorsChairmanMember", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Board of Directors Chairman [Member]", "label": "Board of Directors Chairman [Member]", "documentation": "Leader of board of directors." } } }, "auth_ref": [ "r772" ] }, "abvc_BraingenesisBiotechnologyCoLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BraingenesisBiotechnologyCoLtdMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Braingenesis Biotechnology Co., Ltd. [Member]", "label": "Braingenesis Biotechnology Co Ltd Member" } } }, "auth_ref": [] }, "us-gaap_BuildingAndBuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingAndBuildingImprovementsMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and Leasehold Improvements [Member]", "label": "Building and Building Improvements [Member]", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities and any addition, improvement, or renovation to the structure, for example, but not limited to, interior masonry, interior flooring, electrical, and plumbing." } } }, "auth_ref": [] }, "us-gaap_BuildingImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BuildingImprovementsMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Buildings and leasehold improvements [Member]", "label": "Building Improvements [Member]", "documentation": "Addition, improvement, or renovation to a facility held for productive use including, but not limited to, office, production, storage and distribution facilities." } } }, "auth_ref": [ "r146" ] }, "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationAsset1", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock consideration", "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Asset", "documentation": "Amount of increase (decrease) in the value of right to a contingent consideration asset." } } }, "auth_ref": [ "r480", "r761" ] }, "abvc_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedExpenseAndOtherCurrentLiabilities", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Accrued expense", "documentation": "Accrued expense.", "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Expense And Other Current Liabilities" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAssets", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total assets acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assets", "documentation": "Amount of assets acquired at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesLongTermDebt", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Due to Director", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Long-Term Debt", "documentation": "Amount of long-term debt due within one year or within the normal operating cycle, if longer, assumed at the acquisition date." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Total liabilities acquired", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net", "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r82", "r83" ] }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAcquisitionwasAccountedforBusinessCombinationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total consideration (Intangible assets)", "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net", "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed." } } }, "auth_ref": [ "r83" ] }, "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock", "presentation": [ "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusiness" ], "lang": { "en-us": { "role": { "terseLabel": "ORGANIZATION AND DESCRIPTION OF BUSINESS", "label": "Business Description and Basis of Presentation [Text Block]", "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r109", "r142", "r143" ] }, "abvc_CTBCBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CTBCBankMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "terseLabel": "CTBC Bank [Member]", "label": "CTBCBank Member" } } }, "auth_ref": [] }, "us-gaap_Cash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Cash", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash received", "label": "Cash", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r180", "r564", "r604", "r629", "r727", "r739", "r752" ] }, "us-gaap_CashAndCashEquivalentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents and restricted cash", "label": "Cash and Cash Equivalents [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r48", "r217", "r706" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r49" ] }, "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted Cash", "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]", "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits." } } }, "auth_ref": [ "r49", "r162" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning", "periodEndLabel": "Ending", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r48", "r139", "r250" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net increase (decrease) in cash and cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r3", "r139" ] }, "us-gaap_CashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalent", "label": "Cash Equivalents, at Carrying Value", "documentation": "Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r752", "r844" ] }, "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid during the year for:", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]" } } }, "auth_ref": [] }, "abvc_CathayBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CathayBankMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cathay Bank [Member]", "label": "Cathay Bank Member" } } }, "auth_ref": [] }, "abvc_CathayUnitedBankMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CathayUnitedBankMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cathay United Bank [Member]", "label": "Cathay United Bank Member" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfStockLineItems", "presentation": [ "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business[Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r223", "r224", "r225", "r289", "r384", "r385", "r387", "r389", "r392", "r397", "r399", "r592", "r593", "r594", "r595", "r720", "r742", "r763" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r72" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Initial exercise price (in Dollars per share)", "verboseLabel": "Warrant exercise price (in Dollars per share)", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r400" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-funded warrants shares", "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r400" ] }, "abvc_CodevelopmentagreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CodevelopmentagreementMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Co-Dev Agreement [Member]", "label": "Codevelopmentagreement Member" } } }, "auth_ref": [] }, "abvc_CollaborativeAgreementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CollaborativeAgreementsAbstract", "lang": { "en-us": { "role": { "label": "Collaborative Agreements [Abstract]" } } }, "auth_ref": [] }, "abvc_CollaborativeAgreementsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CollaborativeAgreementsDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Agreements (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_CollaborativeArrangementDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreements" ], "lang": { "en-us": { "role": { "terseLabel": "COLLABORATIVE AGREEMENTS", "label": "Collaborative Arrangement Disclosure [Text Block]", "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants." } } }, "auth_ref": [ "r182", "r184", "r195" ] }, "us-gaap_CollaborativeArrangementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaborative Agreement [Member]", "label": "Collaborative Arrangement [Member]", "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity." } } }, "auth_ref": [ "r481" ] }, "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Agreements [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r481" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r35", "r105", "r563", "r620" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/CommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r148", "r339", "r340", "r690", "r780" ] }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommitmentsAndContingenciesPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies." } } }, "auth_ref": [ "r65", "r691" ] }, "abvc_CommonSharesIssuedForDebtConversion": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CommonSharesIssuedForDebtConversion", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in accrued expenses and other current liabilities", "documentation": "Amount of common shares issued for debt conversion.", "label": "Common Shares Issued For Debt Conversion" } } }, "auth_ref": [] }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate shares (in Shares)", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": [ "r36" ] }, "us-gaap_CommonStockConvertibleConversionPriceDecrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceDecrease", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock conversion price (in Dollars per share)", "label": "Common Stock, Convertible, Conversion Price, Decrease", "documentation": "Per share decrease in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r400" ] }, "us-gaap_CommonStockConvertibleConversionPriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockConvertibleConversionPriceIncrease", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock at an initial conversion price (in Dollars per share)", "label": "Common Stock, Convertible, Conversion Price, Increase", "documentation": "Per share increase in conversion price of convertible common stock. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r400" ] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "verboseLabel": "Common Stock [Member]", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r729", "r730", "r731", "r733", "r734", "r735", "r736", "r768", "r769", "r821", "r847", "r851" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in Dollars per share)", "verboseLabel": "Common stock per share price", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r118", "r621" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued", "verboseLabel": "Common shares, issued (in Shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r118" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r118", "r621", "r641", "r851", "r852" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, $0.001 par value, 100,000,000 authorized, 7,940,298 and 3,286,190 shares issued and outstanding as of December 31, 2023 and 2022, respectively(1)", "verboseLabel": "Value of new shares issued", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r118", "r566", "r727" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r44", "r232", "r234", "r241", "r558", "r579" ] }, "abvc_ConcentrationOfClientsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConcentrationOfClientsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Clients", "label": "Concentration Of Clients Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConcentrationRiskCreditRisk", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r107", "r186" ] }, "srt_CondensedBalanceSheetStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedBalanceSheetStatementTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statement [Table]", "documentation": "Disclosure of information about condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r198", "r259", "r743" ] }, "srt_CondensedBalanceSheetStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedBalanceSheetStatementsCaptionsLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "label": "Condensed Balance Sheet Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r199", "r259", "r743" ] }, "srt_CondensedIncomeStatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedIncomeStatementTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statement [Table]", "documentation": "Disclosure of information about condensed income statement including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r199", "r259", "r743" ] }, "srt_CondensedIncomeStatementsCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "CondensedIncomeStatementsCaptionsLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "label": "Condensed Income Statements, Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r199", "r259", "r743" ] }, "srt_ConsolidatedEntitiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ConsolidatedEntitiesAxis", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]", "documentation": "Information by consolidated entity or group of entities." } } }, "auth_ref": [ "r201", "r259", "r483", "r484", "r487", "r488", "r535", "r701", "r748", "r749", "r750", "r781", "r784", "r785" ] }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConstructionInProgressMember", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-Progress [Member]", "verboseLabel": "Construction in Progress [Member]", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": [] }, "abvc_ConstructioninProgressPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConstructioninProgressPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Construction-in-Progress", "documentation": "Disclosure of accounting policy for construction-in-progress.", "label": "Constructionin Progress Policy Text Block" } } }, "auth_ref": [] }, "abvc_ConsultantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConsultantMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Consultant [Member]", "label": "Consultant Member" } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": [ "r402", "r403", "r406" ] }, "us-gaap_ConversionOfStockAmountConverted1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockAmountConverted1", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "http://www.abvcpharma.com/role/StockOptionsDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted amount (in Dollars)", "verboseLabel": "Converted salaries and consulting fees (in Dollars)", "netLabel": "Conversion of Stock, Amount Converted (in Dollars)", "label": "Conversion of Stock, Amount Converted", "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_ConversionOfStockDescription": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockDescription", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion of shares, description", "label": "Conversion of Stock, Description", "documentation": "A unique description of a noncash or part noncash stock conversion. The description would be expected to include sufficient information to provide an understanding of the nature and purpose of the conversion. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_ConversionOfStockSharesConverted1": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConversionOfStockSharesConverted1", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Converted shares (in Shares)", "label": "Conversion of Stock, Shares Converted", "documentation": "The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "abvc_ConversionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConversionPricePerShare", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/StockOptionsDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price per share (in Dollars per share)", "verboseLabel": "Conversion price per share", "documentation": "Conversion price per share.", "label": "Conversion Price Per Share" } } }, "auth_ref": [] }, "us-gaap_ConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebt", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible debenture", "label": "Convertible Debt", "documentation": "Including the current and noncurrent portions, carrying amount of debt identified as being convertible into another form of financial instrument (typically the entity's common stock) as of the balance sheet date, which originally required full repayment more than twelve months after issuance or greater than the normal operating cycle of the company." } } }, "auth_ref": [ "r21", "r165", "r843" ] }, "us-gaap_ConvertibleDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleDebtMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Debt [Member]", "verboseLabel": "Convertible Note [Member]", "label": "Convertible Debt [Member]", "documentation": "Borrowing which can be exchanged for a specified number of another security at the option of the issuer or the holder, for example, but not limited to, the entity's common stock." } } }, "auth_ref": [ "r150", "r355", "r356", "r366", "r367", "r368", "r372", "r373", "r374", "r375", "r376", "r715", "r716", "r717", "r718", "r719" ] }, "us-gaap_ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleLongtermNotesPayableCurrentAndNoncurrentAbstract", "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayable", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible note payable", "label": "Convertible Notes Payable", "documentation": "Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r21", "r165", "r843" ] }, "us-gaap_ConvertibleNotesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible notes payable \u2013 third parties, net", "label": "Convertible Notes Payable, Current", "documentation": "Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder." } } }, "auth_ref": [ "r30" ] }, "abvc_ConvertibleNotesPayableDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConvertibleNotesPayableDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_ConvertibleNotesPayableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ConvertibleNotesPayableMember", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Note [Member]", "verboseLabel": "Convertible Notes Payable [Member]", "label": "Convertible Notes Payable [Member]", "documentation": "Written promise to pay a note which can be exchanged for a specified quantity of securities (typically common stock), at the option of the issuer or the holder." } } }, "auth_ref": [ "r114", "r164" ] }, "abvc_ConvertibleNotesPayablePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ConvertibleNotesPayablePolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Convertible Notes Payable", "documentation": "Disclosure of accounting policy for convertible notes payable.", "label": "Convertible Notes Payable Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Licensing rights", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": [ "r129", "r543" ] }, "us-gaap_CostOfRevenue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CostOfRevenue", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Cost of revenues", "label": "Cost of Revenue", "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period." } } }, "auth_ref": [ "r130", "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r499", "r782" ] }, "us-gaap_CreditDerivativeTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CreditDerivativeTerm1", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant term", "label": "Credit Derivative, Term", "documentation": "Term of the credit risk derivative contract, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r19" ] }, "abvc_CumulativeTransactionAdjustments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "CumulativeTransactionAdjustments", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Cumulative transaction adjustments", "documentation": "The amount of cumulative transaction adjustments.", "label": "Cumulative Transaction Adjustments" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Current:", "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentFederalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentFederalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Current Federal Tax Expense (Benefit)", "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r744", "r766", "r819" ] }, "us-gaap_CurrentForeignTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentForeignTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Current Foreign Tax Expense (Benefit)", "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r744", "r766" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current", "label": "Current Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations." } } }, "auth_ref": [ "r160", "r470", "r476", "r766" ] }, "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Income Tax Expense [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CurrentStateAndLocalTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Current State and Local Tax Expense (Benefit)", "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r744", "r766", "r819" ] }, "us-gaap_DebtConversionConvertedInstrumentRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionConvertedInstrumentRate", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock conversion price", "label": "Debt Conversion, Converted Instrument, Rate", "documentation": "Dividend or interest rate associated with the financial instrument issued in exchange for the original debt being converted in a noncash or part noncash transaction. Noncash are transactions that affect recognized assets or liabilities but that do not result in cash receipts or cash payments. Part noncash refers to that portion of the transaction not resulting in cash receipts or cash payments." } } }, "auth_ref": [ "r51", "r53" ] }, "us-gaap_DebtConversionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtConversionLineItems", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "label": "Convertible Notes Payable [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayable" ], "lang": { "en-us": { "role": { "terseLabel": "CONVERTIBLE NOTES PAYABLE", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": [ "r149", "r252", "r354", "r360", "r361", "r362", "r363", "r364", "r365", "r370", "r377", "r378", "r380" ] }, "us-gaap_DebtInstrumentAnnualPrincipalPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAnnualPrincipalPayment", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Annual Principal Payment", "documentation": "Amount of the total principal payments made during the annual reporting period." } } }, "auth_ref": [ "r21" ] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentAxis", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": [ "r21", "r114", "r115", "r164", "r165", "r259", "r355", "r356", "r357", "r358", "r359", "r361", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r514", "r715", "r716", "r717", "r718", "r719", "r764" ] }, "us-gaap_DebtInstrumentConvertibleConversionPrice1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleConversionPrice1", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "label": "Debt Instrument, Convertible, Conversion Price", "documentation": "The price per share of the conversion feature embedded in the debt instrument." } } }, "auth_ref": [ "r151", "r357" ] }, "us-gaap_DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleIfConvertedValueInExcessOfPrincipal", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Debt Instrument, Convertible, If-converted Value in Excess of Principal", "documentation": "The amount by which the convertible debt's if-converted value exceeds its principle amount at the balance sheet date, regardless of whether the instrument is currently convertible. This element applies to public companies only." } } }, "auth_ref": [ "r67" ] }, "us-gaap_DebtInstrumentConvertibleThresholdTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentConvertibleThresholdTradingDays", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading days", "label": "Debt Instrument, Convertible, Threshold Trading Days", "documentation": "Threshold number of specified trading days that common stock price to conversion price of convertible debt instruments must exceed threshold percentage within a specified consecutive trading period to trigger conversion feature." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentFaceAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFaceAmount", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Pay lind an amount", "verboseLabel": "Principal amount", "netLabel": "Principal amount (in Dollars)", "label": "Debt Instrument, Face Amount", "documentation": "Face (par) amount of debt instrument at time of issuance." } } }, "auth_ref": [ "r97", "r99", "r355", "r514", "r716", "r717" ] }, "us-gaap_DebtInstrumentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentFeeAmount", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research fee", "label": "Debt Instrument, Fee Amount", "documentation": "Amount of the fee that accompanies borrowing money under the debt instrument." } } }, "auth_ref": [ "r33" ] }, "us-gaap_DebtInstrumentIncreaseAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIncreaseAccruedInterest", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued convertible interest", "verboseLabel": "Accrued interest", "label": "Debt Instrument, Increase, Accrued Interest", "documentation": "Increase for accrued, but unpaid interest on the debt instrument for the period." } } }, "auth_ref": [ "r764" ] }, "us-gaap_DebtInstrumentInterestRateEffectivePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateEffectivePercentage", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rate", "label": "Debt Instrument, Interest Rate, Effective Percentage", "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium." } } }, "auth_ref": [ "r32", "r97", "r381", "r514" ] }, "us-gaap_DebtInstrumentInterestRateIncreaseDecrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateIncreaseDecrease", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Bear interest rate", "label": "Debt Instrument, Interest Rate, Increase (Decrease)", "documentation": "Incremental percentage increase (decrease) in the stated rate on a debt instrument." } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentInterestRateTerms": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentInterestRateTerms", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement, description", "label": "Debt Instrument, Interest Rate Terms", "documentation": "Description of the interest rate as being fixed or variable, and, if variable, identification of the index or rate on which the interest rate is based and the number of points or percentage added to that index or rate to set the rate, and other pertinent information, such as frequency of rate resets." } } }, "auth_ref": [ "r32" ] }, "us-gaap_DebtInstrumentIssuedPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentIssuedPrincipal", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan principal amount", "label": "Debt Instrument, Issued, Principal", "documentation": "Amount of principal of debt issued." } } }, "auth_ref": [ "r592" ] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentLineItems", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r259", "r355", "r356", "r357", "r358", "r359", "r361", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r379", "r514", "r715", "r716", "r717", "r718", "r719", "r764" ] }, "us-gaap_DebtInstrumentMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentMaturityDate", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Debt Instrument, Maturity Date", "documentation": "Date when the debt instrument is scheduled to be fully repaid, in YYYY-MM-DD format." } } }, "auth_ref": [ "r194", "r715", "r822" ] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentNameDomain", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": [ "r34", "r259", "r355", "r356", "r357", "r358", "r359", "r361", "r366", "r367", "r368", "r369", "r371", "r372", "r373", "r374", "r375", "r376", "r514", "r715", "r716", "r717", "r718", "r719", "r764" ] }, "us-gaap_DebtInstrumentRepaidPrincipal": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentRepaidPrincipal", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repaid loan", "label": "Debt Instrument, Repaid, Principal", "documentation": "Amount of principal of debt repaid." } } }, "auth_ref": [ "r595" ] }, "us-gaap_DebtInstrumentTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DebtInstrumentTerm", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument term", "label": "Debt Instrument, Term", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementWithIndividualExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredCompensationArrangementWithIndividualExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price (in Dollars per share)", "label": "Deferred Compensation Arrangement with Individual, Exercise Price", "documentation": "The per share price that the individual must pay to acquire shares under the deferred compensation arrangement." } } }, "auth_ref": [ "r74" ] }, "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Federal", "label": "Deferred Federal Income Tax Expense (Benefit)", "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r766", "r818", "r819" ] }, "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred:", "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredForeignIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign", "label": "Deferred Foreign Income Tax Expense (Benefit)", "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r160", "r766", "r818" ] }, "us-gaap_DeferredIncomeTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxAssetsNet", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 }, "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, net", "terseLabel": "Deferred tax assets, net", "label": "Deferred Income Tax Assets, Net", "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting." } } }, "auth_ref": [ "r459", "r460" ] }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred tax expense", "label": "Deferred Income Tax Expense (Benefit)", "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations." } } }, "auth_ref": [ "r9", "r160", "r192", "r475", "r476", "r766" ] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total Deferred", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": [ "r141" ] }, "us-gaap_DeferredOfferingCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredOfferingCosts", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Deferred offering cost (in Dollars)", "label": "Deferred Offering Costs", "documentation": "Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period." } } }, "auth_ref": [ "r778" ] }, "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": "us-gaap_DeferredIncomeTaxesAndTaxCredits", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "terseLabel": "State", "label": "Deferred State and Local Income Tax Expense (Benefit)", "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r766", "r818", "r819" ] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "totalLabel": "Deferred tax assets, Gross", "label": "Deferred Tax Assets, Gross", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r465" ] }, "us-gaap_DeferredTaxAssetsNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets (Liability) [Abstract]" } } }, "auth_ref": [] }, "abvc_DeferredTaxAssetsOperatingLeaseAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DeferredTaxAssetsOperatingLeaseAssets", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease assets", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to operating lease assets.", "label": "Deferred Tax Assets Operating Lease Assets" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOperatingLossCarryforwardsForeign", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net operating loss carryforwards", "label": "Deferred Tax Assets, Operating Loss Carryforwards, Foreign", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards." } } }, "auth_ref": [ "r79", "r817" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on impairment of Assets", "label": "Deferred Tax Assets, Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r79", "r817" ] }, "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsPropertyPlantAndEquipment", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amouunt of valuation property", "label": "Deferred Tax Assets, Property, Plant and Equipment", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment." } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsTaxCreditCarryforwards", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Tax credit of investment", "label": "Deferred Tax Assets, Tax Credit Carryforwards", "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards." } } }, "auth_ref": [ "r78", "r79", "r817" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredIncomeTaxAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Valuation allowance", "label": "Deferred Tax Assets, Valuation Allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r466" ] }, "abvc_DefinedBenefitPlanFundedPercentages": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DefinedBenefitPlanFundedPercentages", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tax benefit percentage", "documentation": "Percentage of plan assets to benefit obligation of defined benefit plan.", "label": "Defined Benefit Plan Funded Percentages" } } }, "auth_ref": [] }, "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DefinedContributionPlanEmployerMatchingContributionPercent", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Monthly contribution of employees salaries", "label": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay", "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan." } } }, "auth_ref": [] }, "us-gaap_DepositLiabilitiesAccruedInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DepositLiabilitiesAccruedInterest", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued interest", "label": "Deposit Liabilities, Accrued Interest", "documentation": "Amount of accrued but unpaid interest on deposit liabilities." } } }, "auth_ref": [ "r104" ] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Depreciation", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Depreciation", "verboseLabel": "Depreciation expenses", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": [ "r9", "r63" ] }, "us-gaap_DerivativeFixedInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativeFixedInterestRate", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Derivative, Fixed Interest Rate", "documentation": "Fixed interest rate related to the interest rate derivative." } } }, "auth_ref": [] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Warrants", "label": "Derivatives, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r15", "r90", "r91", "r92", "r93", "r258" ] }, "abvc_DescriptionOfConversionPrice": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DescriptionOfConversionPrice", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price, description", "documentation": "Description of Conversion Price.", "label": "Description Of Conversion Price" } } }, "auth_ref": [] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "DirectorMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Director [Member]", "label": "Director [Member]", "documentation": "Person serving on board of directors." } } }, "auth_ref": [ "r772", "r848" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://www.abvcpharma.com/role/StockOptions" ], "lang": { "en-us": { "role": { "terseLabel": "STOCK OPTIONS", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r411", "r414", "r444", "r445", "r446", "r723" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock Options [Abstract]" } } }, "auth_ref": [] }, "abvc_DocumentAndEntityInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DocumentAndEntityInformationAbstract", "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentInformationTable", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "abvc_DueToADirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DueToADirectorMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due to a Director [Member]", "label": "Due To ADirector Member" } } }, "auth_ref": [] }, "abvc_DueToshareholdersMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "DueToshareholdersMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due to Shareholders [Member]", "label": "Due Toshareholders Member" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "label": "Loss Per Share [Abstract]", "terseLabel": "Net loss per share:", "verboseLabel": "Loss per share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasic", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Dollars per share)", "verboseLabel": "-Basic", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r242", "r265", "r266", "r267", "r268", "r269", "r274", "r277", "r280", "r281", "r282", "r286", "r497", "r498", "r559", "r580", "r710" ] }, "us-gaap_EarningsPerShareBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareBasicAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Loss Per Share [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareDiluted", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "verboseLabel": "-Diluted", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r242", "r265", "r266", "r267", "r268", "r269", "r277", "r280", "r281", "r282", "r286", "r497", "r498", "r559", "r580", "r710" ] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Per Share of Common Stock", "label": "Earnings Per Share, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LossPerShare" ], "lang": { "en-us": { "role": { "terseLabel": "LOSS PER SHARE", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r273", "r283", "r284", "r285" ] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate changes on cash and cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r505" ] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensation", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails", "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Employee stock-based compensation expenses", "verboseLabel": "Recognized stock-based compensation expense (in Dollars)", "label": "Employee Benefits and Share-Based Compensation", "documentation": "Amount of expense for employee benefit and equity-based compensation." } } }, "auth_ref": [] }, "us-gaap_EmployeeBenefitsAndShareBasedCompensationNoncash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EmployeeBenefitsAndShareBasedCompensationNoncash", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total non-employee stock-based compensation expenses", "label": "Employee Benefit and Share-Based Payment Arrangement, Noncash", "documentation": "Amount of noncash expense (reversal of expense) for employee benefits and share-based payment arrangement. Includes, but is not limited to, pension, other postretirement, postemployment and termination benefits." } } }, "auth_ref": [ "r9" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r740" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r740" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r740" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r740" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://www.abvcpharma.com/role/DocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r740" ] }, "us-gaap_EntityWideRevenueMajorCustomerLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EntityWideRevenueMajorCustomerLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Due From Related Parties - Current [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "label": "Equity [Abstract]", "terseLabel": "Equity" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r14", "r211", "r236", "r237", "r238", "r260", "r261", "r262", "r264", "r270", "r272", "r288", "r322", "r323", "r401", "r447", "r448", "r449", "r471", "r472", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r506", "r507", "r508", "r509", "r510", "r511", "r526", "r584", "r585", "r586", "r603", "r667" ] }, "abvc_EquityDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "EquityDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "label": "Equity (Details) [Table]" } } }, "auth_ref": [] }, "srt_EquityMethodInvesteeNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "EquityMethodInvesteeNameDomain", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Domain]", "documentation": "Name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r318", "r319", "r320" ] }, "us-gaap_EquityMethodInvestmentAdditionalInformation": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentAdditionalInformation", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accounting treatments", "label": "Equity Method Investment, Additional Information", "documentation": "This serves as a place to record data that is not required by accounting literature but is useful for readers of the financial statements as it relates to the details of an equity method investment in common stock. Such information may include the amount of change for a change in ownership (equity) percentage in a given period and the amount and type of the consideration given or received in relation to the change in ownership." } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentOwnershipPercentage", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "verboseLabel": "Interest rate percentage", "label": "Equity Method Investment, Ownership Percentage", "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting." } } }, "auth_ref": [ "r318" ] }, "us-gaap_EquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestments", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Method Investments, net", "label": "Equity Method Investments", "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized." } } }, "auth_ref": [ "r297", "r316", "r753", "r775" ] }, "abvc_EquityMethodInvestmentsOwnershipPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "EquityMethodInvestmentsOwnershipPercentage", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "documentation": "Represent the percent value of equity method investments ownership percentage.", "label": "Equity Method Investments Ownership Percentage" } } }, "auth_ref": [] }, "us-gaap_EquityMethodInvestmentsPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsPolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term Equity Investment", "label": "Equity Method Investments [Policy Text Block]", "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received." } } }, "auth_ref": [ "r7", "r94", "r319" ] }, "us-gaap_EquityMethodInvestmentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityMethodInvestmentsTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss on Investment in Equity Securities", "label": "Equity Method Investments [Table Text Block]", "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information." } } }, "auth_ref": [ "r317" ] }, "abvc_EquityMethodLongTermInvestment": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "EquityMethodLongTermInvestment", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Equity method long term investment (in Shares)", "documentation": "Equity method long term investment.", "label": "Equity Method Long Term Investment" } } }, "auth_ref": [] }, "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquitySecuritiesFvNiRealizedGainLoss", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 5.0 }, "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 14.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Loss on investment in equity securities", "negatedLabel": "Loss on investment in equity securities", "label": "Equity Securities, FV-NI, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI)." } } }, "auth_ref": [ "r581", "r774" ] }, "abvc_EugeneJiangMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "EugeneJiangMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Eugene Jiang [Member]", "label": "Eugene Jiang Member" } } }, "auth_ref": [] }, "abvc_EuroAsiaInvestmentFinanceCorpLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "EuroAsiaInvestmentFinanceCorpLtdMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Euro-Asia Investment & Finance Corp Ltd. [Member]", "label": "Euro Asia Investment Finance Corp Ltd Member" } } }, "auth_ref": [] }, "us-gaap_ExciseAndSalesTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ExciseAndSalesTaxes", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/AcquisitionDetails", "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Net Sales", "label": "Excise and Sales Taxes", "documentation": "The amount of excise and sales taxes included in sales and revenues, which are then deducted as a cost of sales. Includes excise taxes, which are applied to specific types of transactions or items (such as gasoline or alcohol); and sales, use and value added taxes, which are applied to a broad class of revenue-producing transactions involving a wide range of goods and services." } } }, "auth_ref": [ "r240" ] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair value of warrants", "verboseLabel": "Fair value of warrants (in Dollars)", "label": "Fair Value Adjustment of Warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r2", "r9" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueOfAssetsAcquired": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FairValueOfAssetsAcquired", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Value of acquired amount", "label": "Fair Value of Assets Acquired", "documentation": "The fair value of assets acquired in noncash investing or financing activities." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_FederalHomeLoanBankAdvancesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FederalHomeLoanBankAdvancesLineItems", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "label": "Bank Loans [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r335", "r336", "r337", "r338", "r544", "r545" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r60", "r61" ] }, "us-gaap_FiscalPeriod": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "FiscalPeriod", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Fiscal Year", "label": "Fiscal Period, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed." } } }, "auth_ref": [ "r85" ] }, "us-gaap_ForeignCurrencyTransactionGainLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionGainLossBeforeTax", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Gain (loss) on foreign exchange changes", "label": "Gain (Loss), Foreign Currency Transaction, before Tax", "documentation": "Amount, before tax, of realized and unrealized gain (loss) from foreign currency transaction." } } }, "auth_ref": [ "r501", "r502", "r503", "r504", "r664" ] }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign-currency Transactions", "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy." } } }, "auth_ref": [ "r500" ] }, "us-gaap_GainLossOnInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnInvestments", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Investment loss", "verboseLabel": "Recognized investment loss", "label": "Gain (Loss) on Investments", "documentation": "Amount of realized and unrealized gain (loss) on investment." } } }, "auth_ref": [ "r134", "r741" ] }, "us-gaap_GainLossOnSalesOfLoansNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GainLossOnSalesOfLoansNet", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net sales", "label": "Gain (Loss) on Sales of Loans, Net", "documentation": "The net gain (loss) resulting from a sale of loans, including adjustments to record loans classified as held-for-sale at the lower-of-cost-or-market and fair value adjustments to loan held for investment purposes." } } }, "auth_ref": [ "r9", "r173" ] }, "abvc_GenePharmIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "GenePharmIncMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "GenePharm Inc. [Member]", "label": "Gene Pharm Inc Member" } } }, "auth_ref": [] }, "abvc_GenePharmInctheGenePharmMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "GenePharmInctheGenePharmMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "GenePharm Inc. (the \u201cGenePharm\u201d) [Member]", "label": "Gene Pharm Incthe Gene Pharm Member" } } }, "auth_ref": [] }, "abvc_GenepharmBiotechCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "GenepharmBiotechCorporationMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Genepharm Biotech Corporation [Member]", "label": "Genepharm Biotech Corporation Member" } } }, "auth_ref": [] }, "us-gaap_GeneralPartnersCapitalAccount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GeneralPartnersCapitalAccount", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Market capitalization", "label": "General Partners' Capital Account", "documentation": "The amount of the general partner's ownership interest." } } }, "auth_ref": [ "r155" ] }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets." } } }, "auth_ref": [ "r12", "r59" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 8.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Impairment loss", "label": "Goodwill, Impairment Loss", "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized." } } }, "auth_ref": [ "r9", "r332", "r333", "r334", "r714" ] }, "us-gaap_GrossProfit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "GrossProfit", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "totalLabel": "Gross (loss) profit", "terseLabel": "Gross profit", "label": "Gross Profit", "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity." } } }, "auth_ref": [ "r128", "r254", "r290", "r299", "r303", "r305", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r499", "r712", "r782" ] }, "us-gaap_HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "HealthCareOrganizationAllowanceForDoubtfulAccountsPercentageOfAccountsReceivable", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Account receivable percentage", "label": "Health Care Organization, Allowance for Doubtful Accounts, Percentage of Accounts Receivable", "documentation": "Ratio of the allowance for doubtful accounts to accounts receivable, expressed as a percentage, for health care organizations." } } }, "auth_ref": [] }, "abvc_ImpairmentOfEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ImpairmentOfEquityInvestments", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of equity investments", "documentation": "Impairment of equity investments.", "label": "Impairment Of Equity Investments" } } }, "auth_ref": [] }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Impairment of Long-Lived Assets", "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets." } } }, "auth_ref": [ "r0", "r147" ] }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before provision income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r1", "r125", "r171", "r290", "r299", "r303", "r305", "r560", "r575", "r712" ] }, "us-gaap_IncomeLossFromEquityMethodInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeLossFromEquityMethodInvestments", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLossonInvestmentinEquitySecuritiesTable", "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Share of losses from investments accounted for using the equity method", "verboseLabel": "Share of equity method investee losses", "label": "Income (Loss) from Equity Method Investments", "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)." } } }, "auth_ref": [ "r9", "r126", "r170", "r295", "r316", "r574" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/IncomeTaxes" ], "lang": { "en-us": { "role": { "terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information." } } }, "auth_ref": [ "r255", "r456", "r462", "r463", "r468", "r473", "r477", "r478", "r479", "r597" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ProfitLoss", "weight": -1.0, "order": 2.0 }, "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "http://www.abvcpharma.com/role/ScheduleofIncomeTaxExpenseTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total provision for income taxes", "terseLabel": "Provision for income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r179", "r193", "r271", "r272", "r296", "r461", "r474", "r582" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Income Taxes", "label": "Income Tax, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r235", "r457", "r458", "r463", "r464", "r467", "r469", "r591" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaid", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Income taxes paid", "label": "Income Taxes Paid", "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income." } } }, "auth_ref": [ "r47", "r50" ] }, "us-gaap_IncomeTaxesPaidNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncomeTaxesPaidNetAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInAccruedIncomeTaxesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInAccruedIncomeTaxesPayable", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in Taxes payables", "label": "Increase (Decrease) in Income Taxes Payable", "documentation": "The increase (decrease) during the period in the amount due for taxes based on the reporting entity's earnings or attributable to the entity's income earning process (business presence) within a given jurisdiction." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in contract liabilities", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": [ "r541", "r761" ] }, "us-gaap_IncreaseDecreaseInDueFromRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueFromRelatedParties", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in due from related parties", "label": "Increase (Decrease) in Due from Related Parties", "documentation": "The increase (decrease) during the reporting period in receivables to be collected from other entities that could exert significant influence over the reporting entity." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInDueToRelatedPartiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInDueToRelatedPartiesCurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 12.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in due to related parties", "label": "Increase (Decrease) in Due to Related Parties, Current", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations to be paid to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entities' management; an entity and its principal owners, management, or member of their immediate families, affiliates, or other parties with the ability to exert significant influence." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Changes in operating assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 16.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Decrease (increase) in prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r8" ] }, "us-gaap_IncreaseDecreaseInSecurityDeposits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "IncreaseDecreaseInSecurityDeposits", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Increase (decrease) in tenant security deposit", "label": "Increase (Decrease) in Security Deposits", "documentation": "The increase (decrease) during the reporting period in security deposits." } } }, "auth_ref": [ "r8" ] }, "us-gaap_InterestAndDebtExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestAndDebtExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses", "label": "Interest and Debt Expense", "documentation": "Interest and debt related expenses associated with nonoperating financing activities of the entity." } } }, "auth_ref": [ "r11" ] }, "us-gaap_InterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpense", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "terseLabel": "Interest expenses", "label": "Interest Expense", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense." } } }, "auth_ref": [ "r98", "r174", "r239", "r294", "r513", "r651", "r737", "r850" ] }, "us-gaap_InterestExpenseDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestExpenseDebt", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses", "label": "Interest Expense, Debt", "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt." } } }, "auth_ref": [ "r136", "r374", "r382", "r718", "r719" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expense paid", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r245", "r248", "r249" ] }, "us-gaap_InterestPayableCurrentAndNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InterestPayableCurrentAndNoncurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest expenses", "label": "Interest Payable", "documentation": "Amount of interest payable on debt, including, but not limited to, trade payables." } } }, "auth_ref": [ "r104", "r841" ] }, "abvc_InventoryAllowanceForValuationLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "InventoryAllowanceForValuationLosses", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory allowance for valuation losses", "documentation": "Represent the amount of inventory allowance for valuation losses.", "label": "Inventory Allowance For Valuation Losses" } } }, "auth_ref": [] }, "us-gaap_InventoryPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InventoryPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Policy [Policy Text Block]", "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost." } } }, "auth_ref": [ "r181", "r216", "r229", "r329", "r330", "r331", "r542", "r708" ] }, "abvc_InverlewAdvisorsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "InverlewAdvisorsLLCMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Inverlew Advisors, LLC [Member]", "label": "Inverlew Advisors LLCMember" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r133", "r293" ] }, "us-gaap_InvestmentSoldNotYetPurchasedBalancePrincipalAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentSoldNotYetPurchasedBalancePrincipalAmount", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Repaying securities totaling (in Dollars)", "label": "Security Sold Short, Principal Amount", "documentation": "For investments which are quantified by principal amount, principal balance held at close of period." } } }, "auth_ref": [ "r853" ] }, "us-gaap_InvestmentSoldNotYetPurchasedBalanceShares": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentSoldNotYetPurchasedBalanceShares", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Security shares", "label": "Security Sold Short, Shares", "documentation": "Number of securities sold short (the short position) as of the end of the period." } } }, "auth_ref": [ "r679" ] }, "us-gaap_InvestmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "InvestmentTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestments" ], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM INVESTMENTS", "label": "Investment [Text Block]", "documentation": "The entire disclosure for investment." } } }, "auth_ref": [ "r745", "r746", "r773" ] }, "abvc_IssuanceOfPrefundedWarrant": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "IssuanceOfPrefundedWarrant", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of pre-funded warrant", "documentation": "Represents the amount of issuance of pre-funded warrant.", "label": "Issuance Of Prefunded Warrant" } } }, "auth_ref": [] }, "abvc_IssuanceOfStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "IssuanceOfStockValue", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total cash amount", "documentation": "The value of Common stock newly issued. for example : newly issued shares means any common shares issued pursuant to the primary share purchases.", "label": "Issuance Of Stock Value" } } }, "auth_ref": [] }, "abvc_JIANGSMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "JIANGSMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Jiangs [Member]", "label": "JIANGSMember" } } }, "auth_ref": [] }, "abvc_JaimesVargasRussmanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "JaimesVargasRussmanMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Jaimes Vargas Russman [Member]", "label": "Jaimes Vargas Russman Member" } } }, "auth_ref": [] }, "abvc_LaborPensionFundPerMonth": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LaborPensionFundPerMonth", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Labor pension fund per month", "documentation": "Labor pension fund per month.", "label": "Labor Pension Fund Per Month" } } }, "auth_ref": [] }, "us-gaap_LandMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LandMember", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Land [Member]", "label": "Land [Member]", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [ "r788" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Lease Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeaseCostTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeaseCostTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Company\u2019s Lease Expenses", "label": "Lease, Cost [Table Text Block]", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [ "r827" ] }, "abvc_LeaseDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LeaseDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lease (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LeasesOperatingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LeasesOperatingAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Operating Leases have Remaining Lease Terms [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LegalFees", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Placement agent fees and legal fees (in Dollars)", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r131" ] }, "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Minimum Future Annual Payments Under Non-Cancellable Leases", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]", "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position." } } }, "auth_ref": [ "r828" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Total future minimum lease payments, undiscounted", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2024", "label": "Lessee, Operating Lease, Liability, to be Paid, Year One", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: Imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease." } } }, "auth_ref": [ "r520" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases term", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r825" ] }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": [ "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cancellable leases future term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r826" ] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LesseeOperatingLeasesTextBlock", "presentation": [ "http://www.abvcpharma.com/role/Lease" ], "lang": { "en-us": { "role": { "terseLabel": "LEASE", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": [ "r515" ] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities", "label": "Liabilities", "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future." } } }, "auth_ref": [ "r29", "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r484", "r487", "r488", "r499", "r619", "r711", "r739", "r782", "r831", "r832" ] }, "us-gaap_LiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" ], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND EQUITY", "verboseLabel": "LIABILITIES", "label": "Liabilities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities and Equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r123", "r167", "r570", "r727", "r765", "r776", "r823" ] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total Current Liabilities", "terseLabel": "Current Liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r31", "r215", "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r484", "r487", "r488", "r499", "r727", "r782", "r831", "r832" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Current Liabilities", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-current Liabilities", "label": "Liabilities, Noncurrent", "documentation": "Amount of obligation due after one year or beyond the normal operating cycle, if longer." } } }, "auth_ref": [ "r21", "r110", "r111", "r112", "r116", "r254", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r484", "r487", "r488", "r499", "r782", "r831", "r832" ] }, "abvc_LindGlobalFundIILPLindMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LindGlobalFundIILPLindMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lind Global Fund II, LP (\u201cLind\u201d) [Member]", "label": "Lind Global Fund IILPLind Member" } } }, "auth_ref": [] }, "abvc_LindGlobalFundIILPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LindGlobalFundIILPMember", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lind Global Fund II, LP [Member]", "label": "Lind Global Fund IILPMember" } } }, "auth_ref": [] }, "abvc_LindGlobalFundIIMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LindGlobalFundIIMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lind Global Fund II [Member]", "label": "Lind Global Fund IIMember" } } }, "auth_ref": [] }, "abvc_LindReceivedTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LindReceivedTerm", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lind received", "documentation": "The term between lind received.", "label": "Lind Received Term" } } }, "auth_ref": [] }, "abvc_LindWarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LindWarrantMember", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lind Warrant [Member]", "label": "Lind Warrant Member" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Line of credit", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": [ "r26" ] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Credit limit amount", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": [ "r26" ] }, "abvc_LiquidityAndGoingConcernAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LiquidityAndGoingConcernAbstract", "lang": { "en-us": { "role": { "label": "Liquidity and Going Concern [Abstract]" } } }, "auth_ref": [] }, "abvc_LiquidityAndGoingConcernTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LiquidityAndGoingConcernTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LiquidityandGoingConcern" ], "lang": { "en-us": { "role": { "terseLabel": "LIQUIDITY AND GOING CONCERN", "documentation": "The entire disclosure of liquidity and going concern.", "label": "Liquidity And Going Concern Text Block" } } }, "auth_ref": [] }, "abvc_LoanAgreementAndNoteAmountNotExceeding": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LoanAgreementAndNoteAmountNotExceeding", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement and note amount not exceeding", "documentation": "The company pursuant to the loan agreement and note amount not exceeding.", "label": "Loan Agreement And Note Amount Not Exceeding" } } }, "auth_ref": [] }, "abvc_LoanAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LoanAgreementMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan Agreement [Member]", "label": "Loan Agreement Member" } } }, "auth_ref": [] }, "us-gaap_LoansAndLeasesReceivableRelatedParties": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansAndLeasesReceivableRelatedParties", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan agreement amount", "label": "Loans and Leases Receivable, Related Parties", "documentation": "For an unclassified balance sheet, reflects the carrying amount of unpaid loan amounts due from related parties at the balance sheet date." } } }, "auth_ref": [ "r101", "r106" ] }, "us-gaap_LoansPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LoansPayable", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan amount", "label": "Loans Payable", "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer)." } } }, "auth_ref": [ "r21", "r165", "r843" ] }, "us-gaap_LongTermDebtMaturityDate": { "xbrltype": "dateItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermDebtMaturityDate", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maturity date", "label": "Long-Term Debt, Maturity Date", "documentation": "Maturity date of long-term debt, in YYYY-MM-DD format." } } }, "auth_ref": [ "r822" ] }, "us-gaap_LongTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestments", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term investments", "label": "Long-Term Investments", "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle)." } } }, "auth_ref": [ "r218" ] }, "us-gaap_LongTermInvestmentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermInvestmentsAbstract", "lang": { "en-us": { "role": { "label": "Long-Term Investments [Abstract]" } } }, "auth_ref": [] }, "abvc_LongTermInvestmentsDetailsScheduleofExtenttheInvesteeReliesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LongTermInvestmentsDetailsScheduleofExtenttheInvesteeReliesTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) - Schedule of Extent the Investee Relies [Table]" } } }, "auth_ref": [] }, "abvc_LongTermInvestmentsDetailsScheduleofLongTermInvestmentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LongTermInvestmentsDetailsScheduleofLongTermInvestmentTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) - Schedule of Long-Term Investment [Table]" } } }, "auth_ref": [] }, "abvc_LongTermInvestmentsDetailsScheduleofOwnershipPercentagesofEachInvesteeTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LongTermInvestmentsDetailsScheduleofOwnershipPercentagesofEachInvesteeTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) - Schedule of Ownership Percentages of Each Investee [Table]" } } }, "auth_ref": [] }, "abvc_LongTermInvestmentsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LongTermInvestmentsDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "label": "Long-Term Investments (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_LongTermPurchaseCommitmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "LongTermPurchaseCommitmentLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Long-Term Investment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "abvc_LossPerShareDetailsScheduleofLossPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LossPerShareDetailsScheduleofLossPerShareLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Loss Per Share (Details) - Schedule of Loss Per Share [Line Items]" } } }, "auth_ref": [] }, "abvc_LossPerShareDetailsScheduleofLossPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "LossPerShareDetailsScheduleofLossPerShareTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "label": "Loss Per Share (Details) - Schedule of Loss Per Share [Table]" } } }, "auth_ref": [] }, "us-gaap_MachineryAndEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MachineryAndEquipmentMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Machinery and equipment [Member]", "verboseLabel": "Machinery and Equipment [Member]", "label": "Machinery and Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MaximumMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum [Member]", "label": "Maximum [Member]", "documentation": "Upper limit of the provided range." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r410", "r540", "r583", "r609", "r610", "r676", "r678", "r681", "r682", "r684", "r702", "r703", "r713", "r720", "r722", "r728", "r786", "r833", "r834", "r835", "r836", "r837", "r838" ] }, "abvc_MergerAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "MergerAgreementMember", "presentation": [ "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Merger Agreement [Member]", "label": "Merger Agreement Member" } } }, "auth_ref": [] }, "abvc_MilestonePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "MilestonePayments", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payment", "documentation": "Milestone payments.", "label": "Milestone Payments" } } }, "auth_ref": [] }, "abvc_MilestonePaymentsRoyaltyPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "MilestonePaymentsRoyaltyPercentage", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone payments royalty percentage", "documentation": "Milestone payments royalty percentage.", "label": "Milestone Payments Royalty Percentage" } } }, "auth_ref": [] }, "abvc_MilestoneRegulatoryPaymentAmountPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "MilestoneRegulatoryPaymentAmountPeriod", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Milestone regulatory payment amount period", "documentation": "Milestone Regulatory Payment Amount Period.", "label": "Milestone Regulatory Payment Amount Period" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "MinimumMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum [Member]", "label": "Minimum [Member]", "documentation": "Lower limit of the provided range." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r410", "r540", "r583", "r609", "r610", "r676", "r678", "r681", "r682", "r684", "r702", "r703", "r713", "r720", "r722", "r728", "r786", "r833", "r834", "r835", "r836", "r837", "r838" ] }, "us-gaap_MinorityInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "MinorityInterest", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r41", "r166", "r254", "r321", "r345", "r347", "r348", "r349", "r352", "r353", "r499", "r569", "r623" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r247" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from financing activities", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r247" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from investing activities", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/LiquidityandGoingConcernDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "terseLabel": "Net cash from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r139", "r140", "r141" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Cash flows from operating activities", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss attributed to ABVC and subsidiaries", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r127", "r141", "r172", "r213", "r231", "r233", "r238", "r254", "r263", "r265", "r266", "r267", "r268", "r271", "r272", "r278", "r290", "r299", "r303", "r305", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r498", "r499", "r578", "r643", "r665", "r666", "r712", "r737", "r782" ] }, "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss attributable to noncontrolling interests", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r89", "r161", "r231", "r233", "r271", "r272", "r577", "r759" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable", "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Net loss", "verboseLabel": "Net loss attributable to ABVC\u2019s common stockholders", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r244", "r265", "r266", "r267", "r268", "r274", "r275", "r279", "r282", "r290", "r299", "r303", "r305", "r712" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "us-gaap_NoncontrollingInterestMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NoncontrollingInterestMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Non controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." } } }, "auth_ref": [ "r86", "r401", "r768", "r769", "r770", "r851" ] }, "abvc_NonmarketableCostMethodInvestmentsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "NonmarketableCostMethodInvestmentsNet", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Non-marketable Cost Method Investments, net", "documentation": "This item represents the total non marketable cost method investments net included in earnings for the period as a result of selling marketable securities categorized as trading, available-for-sale, or held-to-maturity and any gains or losses realized during the period from the sale of investments accounted for under the cost method of accounting and/or investments that are separately or otherwise not categorized as trading, available-for-sale, or held-to-maturity. Additionally, this item would include any losses recognized for other than temporary impairments (OTTI) of the subject investments in debt and equity securities.", "label": "Nonmarketable Cost Method Investments Net" } } }, "auth_ref": [] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expenses)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r135" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "abvc_NumberOfDirectors": { "xbrltype": "integerItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "NumberOfDirectors", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of directors", "documentation": "Number of directors.", "label": "Number Of Directors" } } }, "auth_ref": [] }, "abvc_NumberOfEmployees": { "xbrltype": "integerItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "NumberOfEmployees", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of employees", "documentation": "Number of employees.", "label": "Number Of Employees" } } }, "auth_ref": [] }, "abvc_NumberOfTradingConversionDays": { "xbrltype": "durationItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "NumberOfTradingConversionDays", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trading days", "documentation": "The days between conversion trading days.", "label": "Number Of Trading Conversion Days" } } }, "auth_ref": [] }, "us-gaap_OfficeEquipmentMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OfficeEquipmentMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Office equipment [Member]", "verboseLabel": "Office Equipment [Member]", "label": "Office Equipment [Member]", "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine." } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingExpensesAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating expenses", "label": "Operating Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "totalLabel": "Loss from operations", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r290", "r299", "r303", "r305", "r712" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease expenses", "label": "Operating Lease, Expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r824" ] }, "us-gaap_OperatingLeaseLeaseIncomeLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeLeasePayments", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for amounts included in the measurement of operating lease liabilities", "label": "Operating Lease, Lease Income, Lease Payments", "documentation": "Amount of operating lease income from lease payments paid and payable to lessor. Excludes variable lease payments not included in measurement of lease receivable." } } }, "auth_ref": [ "r287", "r524" ] }, "us-gaap_OperatingLeaseLeaseIncomeTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLeaseIncomeTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LeaseTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leases have Remaining Lease Terms", "label": "Operating Lease, Lease Income [Table Text Block]", "documentation": "Tabular disclosure of components of income from operating lease." } } }, "auth_ref": [ "r287", "r523" ] }, "abvc_OperatingLeaseLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "OperatingLeaseLiabilities", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDeferredTaxAssetsLiabilityTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "documentation": "Operating lease liabilities amount.", "label": "Operating Lease Liabilities" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofMinimumFutureAnnualPaymentsUnderNonCancellableLeasesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Present value of future minimum lease payments", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r517" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities \u2013 current portion", "verboseLabel": "Operating lease liabilities (current)", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r517" ] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability \u2013 non-current portion", "verboseLabel": "Operating lease liabilities (non-current)", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r517" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofOperatingLeaseshaveRemainingLeaseTermsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r516" ] }, "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } }, "auth_ref": [ "r519", "r726" ] }, "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Operating leases", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r518", "r726" ] }, "us-gaap_OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasedAssetsLineItems", "presentation": [ "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "label": "Lease [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Minimum Future Annual Payments Under Non Cancellable Leases [Abstract]" } } }, "auth_ref": [] }, "abvc_OperatingSubleaseIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "OperatingSubleaseIncome", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Operating sublease income", "documentation": "It represents amount of operating sublease income.", "label": "Operating Sublease Income" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization and Description of Business [Abstract]" } } }, "auth_ref": [] }, "abvc_OrganizationandDescriptionofBusinessDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "OrganizationandDescriptionofBusinessDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "label": "Organization and Description of Business (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Others", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustment", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r5" ] }, "us-gaap_OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due to related parties", "verboseLabel": "Fees paid", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r30", "r727" ] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 13.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Other non-cash expenses", "label": "Other Noncash Income (Expense)", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r141" ] }, "us-gaap_OtherNoncashInvestingAndFinancingItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNoncashInvestingAndFinancingItemsAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash financing and investing activities", "label": "Other Noncash Investing and Financing Items [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expenses)", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r137" ] }, "us-gaap_OtherReceivableAfterAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivableAfterAllowanceForCreditLossNoncurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 9.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due from related parties \u2013 non-current, net", "verboseLabel": "Net", "label": "Other Receivable, after Allowance for Credit Loss, Noncurrent", "documentation": "Amount, after allowance for credit loss, of receivable classified as other and noncurrent." } } }, "auth_ref": [ "r754" ] }, "us-gaap_OtherReceivableAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivableAllowanceForCreditLossNoncurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "negatedLabel": "Less: allowance for expected credit losses accounts", "label": "Other Receivable, Allowance for Credit Loss, Noncurrent", "documentation": "Amount of allowance for credit loss on receivable classified as other and noncurrent." } } }, "auth_ref": [ "r754" ] }, "us-gaap_OtherReceivableBeforeAllowanceForCreditLossNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivableBeforeAllowanceForCreditLossNoncurrent", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due from related parties \u2013 Non-Current", "verboseLabel": "Expected credit losses", "label": "Other Receivable, before Allowance for Credit Loss, Noncurrent", "documentation": "Amount, before allowance for credit loss, of receivable classified as other and noncurrent." } } }, "auth_ref": [ "r777" ] }, "us-gaap_OtherReceivables": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivables", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other receivables", "label": "Other Receivables", "documentation": "Amount due from parties in nontrade transactions, classified as other." } } }, "auth_ref": [ "r226", "r630" ] }, "us-gaap_OtherReceivablesNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherReceivablesNetCurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Due from related parties \u2013 current", "verboseLabel": "Due from related parties - current", "label": "Other Receivables, Net, Current", "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer." } } }, "auth_ref": [] }, "us-gaap_OtherResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherResearchAndDevelopmentExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Other Research and Development Expense", "documentation": "Amount of other research and development expense." } } }, "auth_ref": [ "r816" ] }, "us-gaap_OtherShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "OtherShortTermBorrowings", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Principal amount", "label": "Other Short-Term Borrowings", "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r23", "r618" ] }, "abvc_OtherThanTemporaryImpairmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "OtherThanTemporaryImpairmentPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Other-Than-Temporary Impairment", "documentation": "Disclosure of accounting policy for other than temporary impairment.", "label": "Other Than Temporary Impairment Policy Text Block" } } }, "auth_ref": [] }, "abvc_OutstandingPrincipalAndAccruedInterests": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "OutstandingPrincipalAndAccruedInterests", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding principal and accrued interest", "documentation": "Outstanding principal and accrued interest.", "label": "Outstanding Principal And Accrued Interests" } } }, "auth_ref": [] }, "us-gaap_PaymentsForParticipationLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForParticipationLiabilities", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash amount", "label": "Payments for Participation Liabilities", "documentation": "Cash payments related to participation costs." } } }, "auth_ref": [ "r103" ] }, "us-gaap_PaymentsForPreviousAcquisition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsForPreviousAcquisition", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price", "verboseLabel": "Principal amount (in Dollars)", "label": "Payments for Previous Acquisition", "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition." } } }, "auth_ref": [ "r760" ] }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Purchase of equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": [ "r138" ] }, "abvc_PercentageCommonStocksShares": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageCommonStocksShares", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of common stock shares", "documentation": "Percentage value of common stocks shares.", "label": "Percentage Common Stocks Shares" } } }, "auth_ref": [] }, "abvc_PercentageOfAverageAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageOfAverageAmount", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of average amount", "documentation": "Percentage of average amount.", "label": "Percentage Of Average Amount" } } }, "auth_ref": [] }, "abvc_PercentageOfCashPermium": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageOfCashPermium", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of cash premium", "documentation": "Percentage of cash premium.", "label": "Percentage Of Cash Permium" } } }, "auth_ref": [] }, "abvc_PercentageOfNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageOfNetSales", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of net sales", "documentation": "Percentage of net sales.", "label": "Percentage Of Net Sales" } } }, "auth_ref": [] }, "abvc_PercentageOfOutstandingPrincipalAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageOfOutstandingPrincipalAmount", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of outstanding principal amount", "documentation": "Percentage of outstanding principal amount.", "label": "Percentage Of Outstanding Principal Amount" } } }, "auth_ref": [] }, "abvc_PercentageOfPaymentsUnderCodevelopmentAgreement": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PercentageOfPaymentsUnderCodevelopmentAgreement", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Data and development percentage", "documentation": "Percentage of payments under co-development agreement.", "label": "Percentage Of Payments Under Codevelopment Agreement" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameAxis", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PlanNameDomain", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r789", "r790", "r791", "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814" ] }, "us-gaap_PostemploymentBenefitPlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PostemploymentBenefitPlansPolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Post-retirement and post-employment benefits", "label": "Postemployment Benefit Plans, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for postemployment benefits. Postemployment benefits are benefits provided to former or inactive employees, their beneficiaries, and covered dependents after employment but before retirement, except for: a) benefits provided through a pension or postretirement benefit plan, b) individual deferred compensation arrangements, c) special or contractual termination benefits, and d) stock compensation plans." } } }, "auth_ref": [ "r407" ] }, "us-gaap_PreferredStockConvertibleConversionPrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockConvertibleConversionPrice", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Conversion price (in Dollars per share)", "verboseLabel": "Conversion price", "label": "Preferred Stock, Convertible, Conversion Price", "documentation": "Per share conversion price of preferred stock." } } }, "auth_ref": [ "r386" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in Dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r117", "r384" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r117", "r621" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesIssued", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued", "label": "Preferred Stock, Shares Issued", "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt." } } }, "auth_ref": [ "r117", "r384" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet_Parentheticals" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r117", "r621", "r641", "r851", "r852" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, $0.001 par value, 20,000,000 authorized, nil shares issued and outstanding", "label": "Preferred Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r117", "r565", "r727" ] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expense and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r756" ] }, "us-gaap_PrepaidExpenseNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PrepaidExpenseNoncurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses \u2013 non-current", "label": "Prepaid Expense, Noncurrent", "documentation": "Sum of the carrying amounts as of the balance sheet date of amounts paid in advance for expenses which will be charged against earnings in periods after one year or beyond the operating cycle, if longer." } } }, "auth_ref": [ "r754" ] }, "abvc_PrepaymentForEquityInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PrepaymentForEquityInvestments", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Prepayment for equity investment", "documentation": "Represent the amount of prepayment for equity investment.", "label": "Prepayment For Equity Investments" } } }, "auth_ref": [] }, "abvc_PrepaymentForLongtermInvestmentsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PrepaymentForLongtermInvestmentsNoncurrent", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Prepayment for long-term investments", "documentation": "Prepayment for long-term investments noncurrent.", "label": "Prepayment For Longterm Investments Noncurrent" } } }, "auth_ref": [] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications of Prior Year Presentation", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": [ "r751" ] }, "us-gaap_ProceedsFromConvertibleDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromConvertibleDebt", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from convertible notes payable", "label": "Proceeds from Convertible Debt", "documentation": "The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock", "verboseLabel": "Gross proceeds (in Dollars)", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from issuance of warrants", "verboseLabel": "Warrant gross proceeds (in Dollars)", "label": "Proceeds from Issuance of Warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProceedsFromShortTermDebt", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from short-term bank loans", "label": "Proceeds from Short-Term Debt", "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r45" ] }, "us-gaap_ProfessionalAndContractServicesExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfessionalAndContractServicesExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Placement agent fees and legal fees (in Dollars)", "label": "Professional and Contract Services Expense", "documentation": "Professional and contract service expense includes cost reimbursements for support services related to contracted projects, outsourced management, technical and staff support." } } }, "auth_ref": [] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 }, "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "http://www.abvcpharma.com/role/LiquidityandGoingConcernDetails", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "verboseLabel": "Net loss for the year", "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r213", "r231", "r233", "r246", "r254", "r263", "r271", "r272", "r290", "r299", "r303", "r305", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r482", "r485", "r486", "r498", "r499", "r560", "r576", "r602", "r643", "r665", "r666", "r712", "r724", "r725", "r738", "r759", "r782" ] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "label": "Property and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipment" ], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY AND EQUIPMENT", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r145", "r187", "r190", "r191" ] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Property and equipment, gross", "verboseLabel": "Land with book value", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r146", "r219", "r573" ] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Line Items]", "terseLabel": "Property and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "totalLabel": "Property and equipment, net", "terseLabel": "Property and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": [ "r10", "r561", "r573", "r727" ] }, "us-gaap_PropertyPlantAndEquipmentNetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentNetAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Property and Equipment, net", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": [ "r10", "r187", "r190", "r571" ] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": [ "r146" ] }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated Life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, "auth_ref": [] }, "abvc_PropertyandEquipmentDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PropertyandEquipmentDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "label": "Property and Equipment (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Provision for doubtful accounts", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": [ "r243", "r326" ] }, "us-gaap_PublicUtilityPropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "PublicUtilityPropertyPlantAndEquipmentLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Property and Equipment Under Capital Leases Based on the Following Useful Lives [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "abvc_PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PurchaseOfPropertyAndEquipmentByIssuingCommonStockToAThirdParty", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase of Property and equipment by issuing common stock to a third party", "documentation": "Amount of purchase of property and equipment by issuing common stock to a third party.", "label": "Purchase Of Property And Equipment By Issuing Common Stock To AThird Party" } } }, "auth_ref": [] }, "abvc_PurchaseWarrantTerm": { "xbrltype": "durationItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "PurchaseWarrantTerm", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase warrant term", "documentation": "Term of the purchase warrant.", "label": "Purchase Warrant Term" } } }, "auth_ref": [] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeAxis", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]", "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r408", "r410", "r440", "r441", "r442", "r539", "r540", "r583", "r609", "r610", "r676", "r678", "r681", "r682", "r684", "r702", "r703", "r713", "r720", "r722", "r728", "r731", "r779", "r786", "r834", "r835", "r836", "r837", "r838" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "RangeMember", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]", "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median." } } }, "auth_ref": [ "r341", "r342", "r343", "r344", "r408", "r410", "r440", "r441", "r442", "r539", "r540", "r583", "r609", "r610", "r676", "r678", "r681", "r682", "r684", "r702", "r703", "r713", "r720", "r722", "r728", "r731", "r779", "r786", "r834", "r835", "r836", "r837", "r838" ] }, "us-gaap_ReceivablesFromStockholderMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ReceivablesFromStockholderMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Subscription Receivable", "label": "Receivables from Stockholder [Member]", "documentation": "Category of equity that is due from owners or affiliates of the reporting entity (including due from officers or directors) resulting from the sale of stock before the cash payment is received." } } }, "auth_ref": [] }, "us-gaap_RegulatoryAssetAmortizationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RegulatoryAssetAmortizationPeriod", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Amortization period of the promissory note", "label": "Regulatory Asset, Amortization Period", "documentation": "Amortization period for the recovery of regulatory asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofAccountsReceivableDueFromRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofAccountsReceivableDueFromRelatedPartiesTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) - Schedule of Accounts Receivable Due From Related Parties [Table]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofAmountDuetoRelatedPartiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofAmountDuetoRelatedPartiesLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Amount Due to Related Parties [Line Items]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofAmountDuetoRelatedPartiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofAmountDuetoRelatedPartiesTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) - Schedule of Amount Due to Related Parties [Table]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofDueFromRelatedPartiesCurrentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofDueFromRelatedPartiesCurrentLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) - Schedule of Due From Related Parties - Current [Line Items]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofDueFromRelatedPartiesCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofDueFromRelatedPartiesCurrentTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) - Schedule of Due From Related Parties - Current [Table]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsScheduleofRevenueDueFromRelatedPartiesCurrentTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsScheduleofRevenueDueFromRelatedPartiesCurrentTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) - Schedule of Revenue Due From Related Parties - Current [Table]" } } }, "auth_ref": [] }, "abvc_RelatedPartiesTransactionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RelatedPartiesTransactionsDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Related Parties Transactions (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyDomain", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Domain]", "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r409", "r530", "r531", "r612", "r613", "r614", "r616", "r617", "r640", "r642", "r675" ] }, "us-gaap_RelatedPartyMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyMember", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Related Party", "verboseLabel": "Related Party [Member]", "label": "Related Party [Member]", "documentation": "Party related to reporting entity. Includes, but is not limited to, affiliate, entity for which investment is accounted for by equity method, trust for benefit of employees, and principal owner, management, and members of immediate family." } } }, "auth_ref": [ "r256", "r257", "r530", "r531", "r532", "r533", "r612", "r613", "r614", "r616", "r617", "r640", "r642", "r675" ] }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAmountsOfTransaction", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding balance amount", "label": "Related Party Transaction, Amounts of Transaction", "documentation": "Amount of transactions with related party during the financial reporting period." } } }, "auth_ref": [ "r102", "r530" ] }, "us-gaap_RelatedPartyTransactionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionAxis", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable", "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Axis]", "documentation": "Information by type of related party transaction." } } }, "auth_ref": [ "r530", "r531", "r830" ] }, "us-gaap_RelatedPartyTransactionDescriptionOfTransaction": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDescriptionOfTransaction", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Relationship with the Company and its subsidiaries, description", "label": "Related Party Transaction, Description of Transaction", "documentation": "A description of the related party transaction, including transactions to which no amounts or nominal amounts were ascribed and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements. Examples of common related party transactions are, sales, purchases and transfers of realty and personal property, services received or furnished, loans and leases to and from top management and affiliates." } } }, "auth_ref": [ "r178", "r222", "r521", "r522", "r525", "r529" ] }, "us-gaap_RelatedPartyTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionDomain", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Domain]", "documentation": "Transaction between related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionLineItems", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Related Party Transaction [Line Items]", "terseLabel": "Related Parties Transactions [Line items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r646", "r647", "r650" ] }, "us-gaap_RelatedPartyTransactionPurchasesFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionPurchasesFromRelatedParty", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Due from BHK", "label": "Related Party Transaction, Purchases from Related Party", "documentation": "Purchases during the period (excluding transactions that are eliminated in consolidated or combined financial statements) with related party." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionRate", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Interest rate", "label": "Related Party Transaction, Rate", "documentation": "Identify the stated interest rate per the agreement, for example, leasing and debt arrangements between related parties." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionTermsAndMannerOfSettlement": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionTermsAndMannerOfSettlement", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Description of payment settlement", "label": "Related Party Transaction, Terms and Manner of Settlement", "documentation": "Description of the terms and manner of settlement of the related party transaction." } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Related Parties Transactions [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable" ], "lang": { "en-us": { "role": { "label": "Related Party, Type [Axis]", "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "auth_ref": [ "r409", "r530", "r531", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r612", "r613", "r614", "r616", "r617", "r640", "r642", "r675", "r830" ] }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RelatedPartyTransactionsDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactions" ], "lang": { "en-us": { "role": { "terseLabel": "RELATED PARTIES TRANSACTIONS", "label": "Related Party Transactions Disclosure [Text Block]", "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r527", "r528", "r529", "r531", "r534", "r598", "r599", "r600", "r648", "r649", "r650", "r671", "r673" ] }, "us-gaap_RepaymentsOfShortTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RepaymentsOfShortTermDebt", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "negatedLabel": "Repayment of short-term bank loans", "label": "Repayments of Short-Term Debt", "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r46" ] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development expenses", "label": "Research and Development Expense", "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use." } } }, "auth_ref": [ "r108", "r455", "r839" ] }, "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Research and development cost", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept." } } }, "auth_ref": [ "r816" ] }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ResearchAndDevelopmentExpensePolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Research and Development Expenses", "label": "Research and Development Expense, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process." } } }, "auth_ref": [ "r454" ] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": [ "r752", "r762", "r840", "r844" ] }, "abvc_RestrictedShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RestrictedShares", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Restricted shares (in Shares)", "documentation": "shares of restricted to employee.", "label": "Restricted Shares" } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r120", "r153", "r568", "r587", "r589", "r596", "r622", "r727" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RetainedEarningsMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r211", "r260", "r261", "r262", "r264", "r270", "r272", "r322", "r323", "r447", "r448", "r449", "r471", "r472", "r489", "r491", "r492", "r494", "r496", "r584", "r586", "r603", "r851" ] }, "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueFromContractWithCustomerIncludingAssessedTax", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Collaboration revenue", "label": "Revenue from Contract with Customer, Including Assessed Tax", "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise." } } }, "auth_ref": [ "r291", "r292", "r298", "r301", "r302", "r306", "r307", "r309", "r404", "r405", "r543" ] }, "abvc_RevenueFromRelatedParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RevenueFromRelatedParty", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue - related parties", "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.", "label": "Revenue From Related Party" } } }, "auth_ref": [] }, "us-gaap_RevenueRecognitionPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RevenueRecognitionPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue Recognition", "label": "Revenue [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources." } } }, "auth_ref": [ "r644", "r704", "r709" ] }, "us-gaap_Revenues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "Revenues", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_GrossProfit", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenues", "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)." } } }, "auth_ref": [ "r240", "r254", "r291", "r292", "r298", "r301", "r302", "r306", "r307", "r309", "r321", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r499", "r560", "r782" ] }, "abvc_RgeneCorporationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RgeneCorporationMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable", "http://www.abvcpharma.com/role/ScheduleofLongTermInvestmentTable", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "terseLabel": "Rgene Corporation [Member]", "label": "Rgene Corporation Member" } } }, "auth_ref": [] }, "abvc_RgeneCorporationtheRgeneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RgeneCorporationtheRgeneMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Rgene Corporation (the \u201cRgene\u201d) [Member]", "label": "Rgene Corporationthe Rgene Member" } } }, "auth_ref": [] }, "abvc_RgeneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "RgeneMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofAccountsReceivableDueFromRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable", "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofRevenueDueFromRelatedPartiesCurrentTable", "http://www.abvcpharma.com/role/ScheduleofStatementofOperationTable" ], "lang": { "en-us": { "role": { "terseLabel": "Rgene [Member]", "label": "Rgene Member" } } }, "auth_ref": [] }, "us-gaap_RoyaltyExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "RoyaltyExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/AcquisitionDetails", "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalties", "label": "Royalty Expense", "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property." } } }, "auth_ref": [ "r131" ] }, "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Sale of common shares", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPercentageOfOwnershipAfterTransaction": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SaleOfStockPercentageOfOwnershipAfterTransaction", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Ownership percentage", "label": "Sale of Stock, Percentage of Ownership after Transaction", "documentation": "Percentage of subsidiary's or equity investee's stock owned by parent company after stock transaction." } } }, "auth_ref": [] }, "abvc_ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAccountReceivableDueFromRelatedPartiesTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accounts Receivable Due From Related Parties", "label": "Schedule Of Account Receivable Due From Related Parties Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofDueFromRelatedPartiesNonCurrentTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table]", "documentation": "Schedule itemizing specific types of trade accounts and notes receivable, and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsNotesLoansAndFinancingReceivableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Due From Related Parties - Non Current", "label": "Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block]", "documentation": "Tabular disclosure of the various types of trade accounts and notes receivable and for each the gross carrying value, allowance, and net carrying value as of the balance sheet date. Presentation is categorized by current, noncurrent and unclassified receivables." } } }, "auth_ref": [ "r40" ] }, "us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Expenses and Other Current Liabilities", "label": "Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses." } } }, "auth_ref": [] }, "abvc_ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAccountsReceivableDueFromRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Accounts Receivable Due From Related Parties Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAccruedExpensesAndOtherCurrentLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Accrued Expenses and Other Current Liabilities [Abstract]" } } }, "auth_ref": [] }, "abvc_ScheduleOfAcquisitionWasAccountedForBusinessCombinationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAcquisitionWasAccountedForBusinessCombinationAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Acquisition was Accounted for Business Combination [Abstract]" } } }, "auth_ref": [] }, "abvc_ScheduleOfAmountDueToRelatedPartiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAmountDueToRelatedPartiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Amount Due To Related Parties Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfAmountDueToRelatedPartiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfAmountDueToRelatedPartiesTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amount Due to Related Parties", "documentation": "Tabular disclosure of amount due to related parties.", "label": "Schedule Of Amount Due To Related Parties Table Text Block" } } }, "auth_ref": [] }, "abvc_ScheduleOfBalanceSheetAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfBalanceSheetAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Balance Sheet Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AcquisitionTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Acquisition was Accounted for Business Combination", "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]", "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table does not include leveraged buyouts." } } }, "auth_ref": [ "r80", "r81" ] }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Income Tax Expense", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years." } } }, "auth_ref": [ "r159" ] }, "srt_ScheduleOfCondensedBalanceSheetTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedBalanceSheetTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Balance Sheet", "label": "Condensed Balance Sheet [Table Text Block]", "documentation": "Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r747", "r767" ] }, "srt_ScheduleOfCondensedIncomeStatementTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfCondensedIncomeStatementTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Statement of Operation", "label": "Condensed Income Statement [Table Text Block]", "documentation": "Tabular disclosure of condensed income statement, including, but not limited to, income statements of consolidated entities and consolidation eliminations." } } }, "auth_ref": [ "r747", "r767" ] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/IncomeTaxesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Deferred Tax Assets (Liability)", "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r158" ] }, "abvc_ScheduleOfDueFromRelatedPartiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfDueFromRelatedPartiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Due From Related Parties Current Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfDueFromRelatedPartiesNonCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfDueFromRelatedPartiesNonCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Due From Related Parties Non Current Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfDueFromRelatedPartyTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfDueFromRelatedPartyTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Due From Related Parties - Current", "documentation": "Disclosure of due from related party.", "label": "Schedule Of Due From Related Party Table Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LossPerShareTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Loss Per Share", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r771" ] }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]", "documentation": "Information by name of investment including named security. Excludes entity that is consolidated." } } }, "auth_ref": [ "r318", "r319", "r320" ] }, "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfEquityMethodInvestmentsLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOwnershipPercentagesofEachInvesteeTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Ownership Percentages of Each Investee [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r254", "r318", "r319", "r320", "r321", "r499" ] }, "abvc_ScheduleOfExtentTheInvesteeReliesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfExtentTheInvesteeReliesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Extent The Investee Relies Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfExtentTheInvesteeReliesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfExtentTheInvesteeReliesTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Extent the Investee Relies", "documentation": "Tabular disclosure of extent the investee relies.", "label": "Schedule Of Extent The Investee Relies Table Text Block" } } }, "auth_ref": [] }, "abvc_ScheduleOfLongTermInvestmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfLongTermInvestmentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Long Term Investment Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfLongTermInvestmentTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfLongTermInvestmentTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-Term Investment", "label": "Schedule Of Long Term Investment Table Text Block" } } }, "auth_ref": [] }, "abvc_ScheduleOfLossOnInvestmentInEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfLossOnInvestmentInEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Loss on Investment in Equity Securities [Abstract]" } } }, "auth_ref": [] }, "abvc_ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfOwnershipPercentagesOfEachInvesteeAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Ownership Percentages Of Each Investee Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfOwnershipPercentagesOfInvesteeTableTextBlocks", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Ownership Percentages of Each Investee", "label": "Schedule Of Ownership Percentages Of Investee Table Text Blocks" } } }, "auth_ref": [] }, "abvc_ScheduleOfPropertyAndEquipmentUnderCapitalLeasesBasedOnTheFollowingUsefulLivesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfPropertyAndEquipmentUnderCapitalLeasesBasedOnTheFollowingUsefulLivesAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Property And Equipment Under Capital Leases Based On The Following Useful Lives Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentTable" ], "lang": { "en-us": { "role": { "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": [ "r10" ] }, "abvc_ScheduleOfPropertySubjectToOrAvailableForCapitalLeaseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfPropertySubjectToOrAvailableForCapitalLeaseTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property and Equipment Under Capital Leases Based on the Following Useful Lives", "label": "Schedule Of Property Subject To Or Available For Capital Lease Table Text Block" } } }, "auth_ref": [] }, "abvc_ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfRelatedPartiesOfTheCompanyWithWhomTransactionsAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Related Parties Of The Company With Whom Transactions Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Related Party Transactions, by Related Party [Table]", "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates." } } }, "auth_ref": [ "r100", "r102", "r646", "r647", "r650" ] }, "us-gaap_ScheduleOfRelatedPartyTransactionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfRelatedPartyTransactionsTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Related Parties of the Company with whom Transactions", "label": "Schedule of Related Party Transactions [Table Text Block]", "documentation": "Tabular disclosure of related party transactions. Examples of related party transactions include, but are not limited to, transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners and (d) affiliates." } } }, "auth_ref": [] }, "abvc_ScheduleOfRevenueDueFromRelatedPartiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfRevenueDueFromRelatedPartiesCurrentAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Revenue Due From Related Parties Current Abstract" } } }, "auth_ref": [] }, "abvc_ScheduleOfRevenueDueFromRelatedPartyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfRevenueDueFromRelatedPartyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Revenue Due From Related Parties - Current", "documentation": "Tabular disclosure of information revenue due from related party.", "label": "Schedule Of Revenue Due From Related Party Text Block" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Options Issued and Outstanding", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r17", "r18", "r74" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Stock Options Granted", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r157" ] }, "abvc_ScheduleOfShortTermBankLoanAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfShortTermBankLoanAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Short Term Bank Loan Abstract" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfShortTermDebtTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Debt [Table]", "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ScheduleOfShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ScheduleOfShortTermDebtTextBlock", "presentation": [ "http://www.abvcpharma.com/role/BankLoansTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Short-Term Bank Loan", "label": "Schedule of Short-Term Debt [Table Text Block]", "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation." } } }, "auth_ref": [ "r27" ] }, "abvc_ScheduleOfStatementOfOperationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ScheduleOfStatementOfOperationAbstract", "lang": { "en-us": { "role": { "label": "Schedule Of Statement Of Operation Abstract" } } }, "auth_ref": [] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Security deposits", "label": "Security Deposit", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r754" ] }, "us-gaap_SecurityDepositLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SecurityDepositLiability", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Tenant security deposit", "label": "Security Deposit Liability", "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing." } } }, "auth_ref": [] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "SegmentGeographicalDomain", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Domain]", "documentation": "Geographical area." } } }, "auth_ref": [ "r200", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r307", "r308", "r606", "r607", "r608", "r677", "r680", "r683", "r685", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r705", "r721", "r731", "r787", "r846" ] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Selling, general and administrative expenses", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": [ "r132" ] }, "abvc_ServiceAgreementEligibilityAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ServiceAgreementEligibilityAmount", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service agreement eligibility amount", "documentation": "Service agreement eligibility amount.", "label": "Service Agreement Eligibility Amount" } } }, "auth_ref": [] }, "us-gaap_ServiceAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ServiceAgreementsMember", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Service Agreements [Member]", "label": "Service Agreements [Member]", "documentation": "Limited duration contract between, for example, an electricity transmission customer and an electricity transmission provider for service." } } }, "auth_ref": [ "r84" ] }, "abvc_SeveralLoanAgreementsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "SeveralLoanAgreementsMember", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Several Loan Agreements [Member]", "label": "Several Loan Agreements Member" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 3.0 }, "http://www.abvcpharma.com/role/ConsolidatedCashFlow": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow", "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r8" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAdditionalGeneralDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Options Issued and Outstanding [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "lang": { "en-us": { "role": { "label": "Schedule of Fair Value of Stock Options Granted [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofFairValueofStockOptionsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r441" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofFairValueofStockOptionsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r440" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofFairValueofStockOptionsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Risk free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r442" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r412", "r413", "r415", "r416", "r417", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r432", "r433", "r434", "r435", "r436", "r439", "r440", "r441", "r442", "r443" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding amount (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Forfeitures", "documentation": "Number of shares under non-option equity instrument agreements that were cancelled as a result of occurrence of a terminating event." } } }, "auth_ref": [ "r16" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Granted options to purchase", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Exercisable (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r421" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Forfeited", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Intrinsic Value", "documentation": "The combined weighted average of the accumulated differences between the fair values on underlying shares and exercises prices to acquire such shares as of the grant date on options that were either forfeited or lapsed." } } }, "auth_ref": [ "r76" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Forfeited (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Granted", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value", "documentation": "The grant-date intrinsic value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Granted (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average grant date fair value of options granted (in Dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r433" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Aggregate Intrinsic Value, Outstanding ending balance (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Number of Underlying Shares, Outstanding ending balance (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r419", "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "periodEndLabel": "Weighted-Average Exercise Price Per Share, Outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r419", "r420" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value", "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r436" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Underlying Shares, Vested and expected to vest (in Shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r435" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Issued an aggregate shares of common stock", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options to purchase shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r815" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Forfeited", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r425" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Exercise Price Per Share, Granted", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r423" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based Compensation", "label": "Share-Based Payment Arrangement [Policy Text Block]", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r411", "r418", "r437", "r438", "r439", "r440", "r443", "r450", "r451", "r452", "r453" ] }, "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercisable price per share", "label": "Share-Based Payment Arrangement, Option, Exercise Price Range, Shares Exercisable", "documentation": "The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied." } } }, "auth_ref": [ "r75" ] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharePrice", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share price (in Dollars per share)", "verboseLabel": "Consulting and advisory services value per share (in Dollars per share)", "label": "Share Price", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofFairValueofStockOptionsGrantedTable" ], "lang": { "en-us": { "role": { "terseLabel": "Expected term (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r439" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Intrinsic Value, Exercisable (in Dollars)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r73" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r73" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Outstanding ending balance", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r156" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options vested grant date exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r436" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofOptionsIssuedandOutstandingTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted-Average Contractual Life Remaining in Years, Vested and expected to vest", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur." } } }, "auth_ref": [ "r435" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssued", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails", "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/LongTermInvestmentsDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued (in Shares)", "verboseLabel": "Shares of common stock (in Shares)", "label": "Shares, Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r14" ] }, "us-gaap_SharesIssuedPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesIssuedPricePerShare", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Price per share (in Dollars per share)", "verboseLabel": "Price per share", "label": "Shares Issued, Price Per Share", "documentation": "Per share or per unit amount of equity securities issued." } } }, "auth_ref": [] }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SharesOutstanding", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "periodStartLabel": "Balance (in Shares)", "periodEndLabel": "Balance (in Shares)", "label": "Shares, Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": [] }, "abvc_SharesReceived": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "SharesReceived", "presentation": [ "http://www.abvcpharma.com/role/AcquisitionDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares received (in Shares)", "documentation": "Shares received.", "label": "Shares Received" } } }, "auth_ref": [] }, "us-gaap_ShortTermBankLoansAndNotesPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBankLoansAndNotesPayable", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loan recieved", "label": "Short-Term Bank Loans and Notes Payable", "documentation": "Amount of borrowings from a bank classified as other, maturing within one year or operating cycle, if longer." } } }, "auth_ref": [ "r22", "r615", "r842" ] }, "us-gaap_ShortTermBorrowings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowings", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term bank loans", "verboseLabel": "Total", "label": "Short-Term Debt", "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r113", "r164", "r727", "r842" ] }, "us-gaap_ShortTermBorrowingsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermBorrowingsAbstract", "lang": { "en-us": { "role": { "label": "Bank Loans [ Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtInterestRateIncrease": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtInterestRateIncrease", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Effective interest rates", "label": "Short-Term Debt, Interest Rate Increase", "documentation": "Percentage increase in the stated interest rate on a short-term debt instrument." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Short-Term Bank Loan [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ShortTermDebtTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTextBlock", "presentation": [ "http://www.abvcpharma.com/role/BankLoans" ], "lang": { "en-us": { "role": { "terseLabel": "BANK LOANS", "label": "Short-Term Debt [Text Block]", "documentation": "The entire disclosure for short-term debt." } } }, "auth_ref": [ "r149" ] }, "us-gaap_ShortTermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeAxis", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Axis]", "documentation": "Information by type of short-term debt arrangement." } } }, "auth_ref": [ "r27" ] }, "us-gaap_ShortTermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermDebtTypeDomain", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/ScheduleofShortTermBankLoanTable", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Short-Term Debt, Type [Domain]", "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing." } } }, "auth_ref": [ "r24" ] }, "us-gaap_ShortTermInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShortTermInvestments", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Short-term investments", "label": "Short-Term Investments", "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current." } } }, "auth_ref": [ "r168", "r169", "r755" ] }, "us-gaap_ShorttermDebtAverageOutstandingAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "ShorttermDebtAverageOutstandingAmount", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/BankLoansDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding loan", "verboseLabel": "Balance of outstanding loans", "label": "Short-Term Debt, Average Outstanding Amount", "documentation": "For the form of debt having an initial term of less than one year or less than the normal operating cycle, if longer, average borrowings during the period." } } }, "auth_ref": [ "r196", "r197", "r651" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "label": "Significant Accounting Policies [Text Block]", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r142", "r251" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r39", "r211", "r236", "r237", "r238", "r260", "r261", "r262", "r264", "r270", "r272", "r288", "r322", "r323", "r401", "r447", "r448", "r449", "r471", "r472", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r506", "r507", "r508", "r509", "r510", "r511", "r526", "r584", "r585", "r586", "r603", "r667" ] }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "StatementGeographicalAxis", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "label": "Geographical [Axis]", "documentation": "Information by geographical components." } } }, "auth_ref": [ "r200", "r210", "r307", "r308", "r606", "r607", "r608", "r677", "r680", "r683", "r685", "r689", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r699", "r700", "r705", "r721", "r731", "r787", "r846" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementLineItems", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r260", "r261", "r262", "r288", "r543", "r590", "r605", "r611", "r612", "r613", "r614", "r616", "r617", "r621", "r624", "r625", "r626", "r627", "r628", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r644", "r645", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r667", "r732" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementTable", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed." } } }, "auth_ref": [ "r260", "r261", "r262", "r288", "r543", "r590", "r605", "r611", "r612", "r613", "r614", "r616", "r617", "r621", "r624", "r625", "r626", "r627", "r628", "r631", "r632", "r633", "r634", "r636", "r637", "r638", "r639", "r640", "r642", "r644", "r645", "r652", "r653", "r654", "r655", "r656", "r657", "r658", "r659", "r660", "r661", "r662", "r663", "r667", "r732" ] }, "us-gaap_StockIssued1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssued1", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedCashFlow" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock for conversion of debt", "label": "Stock Issued", "documentation": "The fair value of stock issued in noncash financing activities." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon exercise of convertible notes (in Shares)", "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities", "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r38", "r69", "r153", "r371" ] }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Distribute as Employee Compensation (in Shares)", "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan", "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan." } } }, "auth_ref": [ "r14", "r77", "r117", "r118", "r153" ] }, "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesIssuedForServices", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for consulting service (in Shares)", "verboseLabel": "Common stock to consultants for providing consulting services", "label": "Stock Issued During Period, Shares, Issued for Services", "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for cash (in Shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r14", "r117", "r118", "r153", "r592", "r667", "r686" ] }, "us-gaap_StockIssuedDuringPeriodSharesOther": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesOther", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares of common stock", "label": "Stock Issued During Period, Shares, Other", "documentation": "Number of shares of stock issued attributable to transactions classified as other." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesPurchaseOfAssets": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesPurchaseOfAssets", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for property (in Shares)", "label": "Stock Issued During Period, Shares, Purchase of Assets", "documentation": "Number of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrant (in Shares)", "verboseLabel": "Exercise of pre-funded warrant", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r14", "r117", "r118", "r153", "r424" ] }, "us-gaap_StockIssuedDuringPeriodValueAcquisitions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueAcquisitions", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/LongTermInvestmentsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate amount (in Dollars)", "label": "Stock Issued During Period, Value, Acquisitions", "documentation": "Value of stock issued pursuant to acquisitions during the period." } } }, "auth_ref": [ "r14", "r39", "r153" ] }, "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares upon exercise of convertible notes", "label": "Stock Issued During Period, Value, Conversion of Convertible Securities", "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities." } } }, "auth_ref": [ "r14", "r39", "r153" ] }, "us-gaap_StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Distribute as Employee Compensation", "label": "Stock Issued During Period, Value, Employee Stock Ownership Plan", "documentation": "Aggregate value of stock issued during the period as a result of employee stock ownership plan (ESOP)." } } }, "auth_ref": [ "r14", "r77", "r117", "r118", "r153" ] }, "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueIssuedForServices", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for consulting service", "label": "Stock Issued During Period, Value, Issued for Services", "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for cash", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r14", "r117", "r118", "r153", "r603", "r667", "r686", "r738" ] }, "us-gaap_StockIssuedDuringPeriodValuePurchaseOfAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValuePurchaseOfAssets", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common shares for property", "label": "Stock Issued During Period, Value, Purchase of Assets", "documentation": "Value of shares of stock issued during the period as part of a transaction to acquire assets that do not qualify as a business combination." } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise of pre-funded warrant", "label": "Stock Issued During Period, Value, Stock Options Exercised", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r14", "r39", "r153" ] }, "us-gaap_StockOptionExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionExercisePriceIncrease", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Exercise price per share (in Dollars per share)", "verboseLabel": "Common stock , exercise price", "label": "Stock Option, Exercise Price, Increase", "documentation": "Per share increase in exercise price of option. Excludes change due to standard antidilution provision and option granted under share-based payment arrangement." } } }, "auth_ref": [ "r400" ] }, "us-gaap_StockOptionPlanExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockOptionPlanExpense", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Stock options", "label": "Stock or Unit Option Plan Expense", "documentation": "Amount of noncash expense for option under share-based payment arrangement." } } }, "auth_ref": [ "r9" ] }, "abvc_StockOptionsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "StockOptionsDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "label": "Stock Options (Details) [Table]" } } }, "auth_ref": [] }, "abvc_StockReverseSplitsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "StockReverseSplitsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Stock Reverse Split", "documentation": "Disclosure of accounting policy for stock reverse splits.", "label": "Stock Reverse Splits Policy Text Block" } } }, "auth_ref": [] }, "abvc_StockbasedCompensationForServices": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "StockbasedCompensationForServices", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation for services", "documentation": "It represents stock-based compensation for services.", "label": "Stockbased Compensation For Services" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ScheduleofBalanceSheetTable" ], "lang": { "en-us": { "role": { "totalLabel": "Total Stockholders\u2019 equity", "terseLabel": "Stockholders\u2019 Equity", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r118", "r121", "r122", "r144", "r623", "r641", "r668", "r669", "r727", "r739", "r765", "r776", "r823", "r851" ] }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet", "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "totalLabel": "Total Equity", "periodStartLabel": "Balance", "periodEndLabel": "Balance", "label": "Equity, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity." } } }, "auth_ref": [ "r86", "r87", "r88", "r211", "r212", "r237", "r260", "r261", "r262", "r264", "r270", "r322", "r323", "r401", "r447", "r448", "r449", "r471", "r472", "r489", "r490", "r491", "r492", "r493", "r494", "r496", "r506", "r507", "r511", "r526", "r585", "r586", "r601", "r623", "r641", "r668", "r669", "r687", "r738", "r765", "r776", "r823", "r851" ] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://www.abvcpharma.com/role/Equity" ], "lang": { "en-us": { "role": { "terseLabel": "EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r152", "r253", "r383", "r385", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r398", "r401", "r495", "r670", "r672", "r688" ] }, "us-gaap_StockholdersEquityNoteSubscriptionsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityNoteSubscriptionsReceivable", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 6.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Stock subscription receivable", "label": "Stockholders' Equity Note, Subscriptions Receivable", "documentation": "Note received instead of cash as contribution to equity. The transaction may be a sale of capital stock or a contribution to paid-in capital." } } }, "auth_ref": [ "r68", "r117", "r118", "r121", "r674" ] }, "us-gaap_StockholdersEquityReverseStockSplit": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StockholdersEquityReverseStockSplit", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Stock reverse split description", "label": "Stockholders' Equity, Reverse Stock Split", "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements." } } }, "auth_ref": [ "r154" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventLineItems", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Line Items]", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r512", "r537" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventMember", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Subsequent Event [Member]", "label": "Subsequent Event [Member]", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r512", "r537" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r512", "r537" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r512", "r537" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "auth_ref": [] }, "abvc_SubsequentEventsDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "SubsequentEventsDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Events (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://www.abvcpharma.com/role/SubsequentEvents" ], "lang": { "en-us": { "role": { "terseLabel": "SUBSEQUENT EVENTS", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r536", "r538" ] }, "us-gaap_SubsidiaryOrEquityMethodInvesteeLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiaryOrEquityMethodInvesteeLineItems", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofExtenttheInvesteeReliesTable" ], "lang": { "en-us": { "role": { "label": "Schedule of Extent the Investee Relies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SubsidiarySaleOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SubsidiarySaleOfStockLineItems", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "abvc_SummaryofSignificantAccountingPoliciesDetailsScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofPropertyandEquipmentUnderCapitalLeasesBasedontheFollowingUsefulLivesTable" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) - Schedule of Property and Equipment Under Capital Leases Based on the Following Useful Lives [Table]" } } }, "auth_ref": [] }, "abvc_SummaryofSignificantAccountingPoliciesDetailsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "SummaryofSignificantAccountingPoliciesDetailsTable", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies (Details) [Table]" } } }, "auth_ref": [] }, "us-gaap_SupplementalDeferredPurchasePrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "SupplementalDeferredPurchasePrice", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Purchase price (in Dollars)", "label": "Supplemental Deferred Purchase Price", "documentation": "A device of credit enhancement where a part of the purchase price for the receivable/ payable is retained to serve as a cash collateral." } } }, "auth_ref": [ "r51", "r52", "r53" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "terseLabel": "Taxes payables", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r28" ] }, "abvc_ThaliaMediaLtdMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ThaliaMediaLtdMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Thalia Media Ltd. [Member]", "label": "Thalia Media Ltd Member" } } }, "auth_ref": [] }, "abvc_TheJiangsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "TheJiangsMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAmountDuetoRelatedPartiesTable", "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "The Jiangs [Member]", "label": "The Jiangs Member" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualAxis", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]", "documentation": "Information by title of individual or nature of relationship to individual or group of individuals." } } }, "auth_ref": [ "r772", "r829" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2023", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails", "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Domain]", "documentation": "Title of individual, or nature of relationship to individual or group of individuals." } } }, "auth_ref": [] }, "abvc_TotalAccountReceivablePercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "TotalAccountReceivablePercentage", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total account receivable percentage", "documentation": "Total account receivable percentage.", "label": "Total Account Receivable Percentage" } } }, "auth_ref": [] }, "abvc_TotalRevenuesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "TotalRevenuesPercentage", "presentation": [ "http://www.abvcpharma.com/role/SummaryofSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total revenues percentage", "documentation": "Total revenues percentage.", "label": "Total Revenues Percentage" } } }, "auth_ref": [] }, "us-gaap_TradeAndOtherAccountsReceivablePolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TradeAndOtherAccountsReceivablePolicy", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable and allowance for expected credit losses accounts", "label": "Accounts Receivable [Policy Text Block]", "documentation": "Disclosure of accounting policy for accounts receivable." } } }, "auth_ref": [ "r175", "r176", "r177", "r312", "r313", "r315" ] }, "abvc_TranslationAdjustmentPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "TranslationAdjustmentPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Translation Adjustment", "documentation": "Disclosure of accounting policy for translation adjustment.", "label": "Translation Adjustment Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_TreasuryStockCommonMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockCommonMember", "presentation": [ "http://www.abvcpharma.com/role/ShareholdersEquityType2or3" ], "lang": { "en-us": { "role": { "terseLabel": "Treasury Stock", "label": "Treasury Stock, Common [Member]", "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury." } } }, "auth_ref": [ "r70" ] }, "us-gaap_TreasuryStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TreasuryStockValue", "crdr": "debit", "calculation": { "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet": { "parentTag": "us-gaap_StockholdersEquity", "weight": -1.0, "order": 7.0 } }, "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedBalanceSheet" ], "lang": { "en-us": { "role": { "negatedLabel": "Treasury stock", "label": "Treasury Stock, Value", "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury." } } }, "auth_ref": [ "r37", "r70", "r71" ] }, "abvc_TwoThousandSixteenEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "TwoThousandSixteenEquityIncentivePlanMember", "presentation": [ "http://www.abvcpharma.com/role/StockOptionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2016 Equity Incentive Plan [Member]", "label": "Two Thousand Sixteen Equity Incentive Plan Member" } } }, "auth_ref": [] }, "us-gaap_TypeOfArrangementAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "TypeOfArrangementAxis", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r481" ] }, "abvc_UnrestrictedCommonShares": { "xbrltype": "sharesItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "UnrestrictedCommonShares", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Unrestricted common stock", "documentation": "The amount of unrestricted common shares.", "label": "Unrestricted Common Shares" } } }, "auth_ref": [] }, "abvc_UpfrontCashPayment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "UpfrontCashPayment", "crdr": "debit", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Upfront cash payment", "documentation": "The amount of upfront payments which are paid during the term of agreement.", "label": "Upfront Cash Payment" } } }, "auth_ref": [] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseOfEstimates", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Use of Estimates", "label": "Use of Estimates, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r56", "r57", "r58", "r183", "r185", "r188", "r189" ] }, "us-gaap_UseRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "UseRightsMember", "presentation": [ "http://www.abvcpharma.com/role/LeaseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "ROU Assets [Member]", "label": "Use Rights [Member]", "documentation": "Legal right to use or benefit from the use of natural resources or access. Examples include, but are not limited to, drilling rights, water rights, air rights, timber cutting rights and route authorities." } } }, "auth_ref": [ "r20" ] }, "abvc_VWAPMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "VWAPMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "VWAP [Member]", "label": "VWAPMember" } } }, "auth_ref": [] }, "abvc_ValuationOfDeferredTaxAssetsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ValuationOfDeferredTaxAssetsPolicyTextBlock", "presentation": [ "http://www.abvcpharma.com/role/AccountingPoliciesByPolicy" ], "lang": { "en-us": { "role": { "terseLabel": "Valuation of Deferred Tax Assets", "documentation": "Disclosure of accounting policy for valuation of deferred tax assets.", "label": "Valuation Of Deferred Tax Assets Policy Text Block" } } }, "auth_ref": [] }, "us-gaap_WarrantExercisePriceIncrease": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantExercisePriceIncrease", "presentation": [ "http://www.abvcpharma.com/role/ConvertibleNotesPayableDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant exercise price (in Dollars per share)", "verboseLabel": "Warrant exercise price", "label": "Warrant, Exercise Price, Increase", "documentation": "Per share increase in exercise price of warrant. Excludes change due to standard antidilution provision." } } }, "auth_ref": [ "r400" ] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WarrantMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/SubsequentEventsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Warrant [Member]", "label": "Warrant [Member]", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r729", "r730", "r733", "r734", "r735", "r736" ] }, "abvc_WeightedAverageDiscountRateAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "WeightedAverageDiscountRateAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Discount Rate:", "label": "Weighted Average Discount Rate Abstract" } } }, "auth_ref": [] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement_Parentheticals", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Diluted", "verboseLabel": "Weighted-average shares outstanding - Diluted", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r276", "r282" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement", "http://www.abvcpharma.com/role/ScheduleofLossPerShareTable" ], "lang": { "en-us": { "role": { "terseLabel": "Basic (in Shares)", "verboseLabel": "Weighted-average shares outstanding - Basic", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r274", "r282" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [ "http://www.abvcpharma.com/role/ConsolidatedIncomeStatement" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average number of common shares outstanding(1):", "label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "abvc_WeightedAverageRemainingLeaseTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "WeightedAverageRemainingLeaseTermAbstract", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofCompanysLeaseExpensesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Remaining Lease Term:", "label": "Weighted Average Remaining Lease Term Abstract" } } }, "auth_ref": [] }, "us-gaap_WorkersCompensationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "WorkersCompensationLiabilityCurrent", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofAccruedExpensesandOtherCurrentLiabilitiesTable" ], "lang": { "en-us": { "role": { "terseLabel": "Accrued compensation and employee benefits", "label": "Workers' Compensation Liability, Current", "documentation": "Carrying value as of the balance sheet date of obligations and payables pertaining to claims incurred of a workers compensation nature. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r30" ] }, "abvc_WorkingCapitalConvertibleLoanPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "WorkingCapitalConvertibleLoanPercentage", "presentation": [ "http://www.abvcpharma.com/role/CollaborativeAgreementsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of working capital convertible loan", "documentation": "Percentage of working capital convertible loan.", "label": "Working Capital Convertible Loan Percentage" } } }, "auth_ref": [] }, "abvc_WorkingCapitalDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "WorkingCapitalDeficit", "crdr": "credit", "presentation": [ "http://www.abvcpharma.com/role/LiquidityandGoingConcernDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Working capital deficit", "documentation": "Working capital deficit value.", "label": "Working Capital Deficit" } } }, "auth_ref": [] }, "abvc_WorkingCapitalPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "WorkingCapitalPercentage", "presentation": [ "http://www.abvcpharma.com/role/RelatedPartiesTransactionsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Additional working capital percentage", "label": "Working Capital Percentage" } } }, "auth_ref": [] }, "abvc_ZheweiXuMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ZheweiXuMember", "presentation": [ "http://www.abvcpharma.com/role/ScheduleofRelatedPartiesoftheCompanywithwhomTransactionsTable" ], "lang": { "en-us": { "role": { "terseLabel": "Zhewei Xu [Member]", "label": "Zhewei Xu Member" } } }, "auth_ref": [] }, "abvc_ZhonghuiMember": { "xbrltype": "domainItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "ZhonghuiMember", "presentation": [ "http://www.abvcpharma.com/role/EquityDetails", "http://www.abvcpharma.com/role/PropertyandEquipmentDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Zhonghui [Member]", "label": "Zhonghui Member" } } }, "auth_ref": [] }, "abvc_royaltiesPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.abvcpharma.com/20231231", "localname": "royaltiesPercentage", "presentation": [ "http://www.abvcpharma.com/role/AcquisitionDetails", "http://www.abvcpharma.com/role/OrganizationandDescriptionofBusinessDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Royalty percentage", "documentation": "royalties percentage.", "label": "royalties Percentage" } } }, "auth_ref": [] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "4", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482338/360-10-05-4" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "20", "Topic": "940", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481913/940-20-25-1" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21D", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-21D" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "835", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "30", "Topic": "350", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c),(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(3)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4K", "Subparagraph": "(a)(1)", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4K" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "31", "Subparagraph": "(i)", "SubTopic": "20", "Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19(b),22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19,20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.19-26)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.20)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.21)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.25)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29,30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-30)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.29-31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.3,4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "210", "SubTopic": "10", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.31)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-15" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-3" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-4" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-5" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "350", "SubTopic": "30", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482130/360-10-45-4" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "460", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482425/460-10-50-8" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "25", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-2" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "20", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481142/505-10-45-2" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481549/505-30-45-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "30", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481520/505-30-50-4" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "40", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480637/718-40-25-10" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-3" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "740", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-8" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-2" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479328/805-10-50-3" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "55", "Paragraph": "37", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479303/805-10-55-37" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479907/805-20-50-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479876/805-20-55-31" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-12" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-15" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-16" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4I", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4I" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "810", "SubTopic": "10", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-1A" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-4" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480434/815-10-50-7" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "25", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482981/835-30-25-12" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "25", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482981/835-30-25-13" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-2" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482925/835-30-45-3" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "835", "SubTopic": "30", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482949/835-30-55-8" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "850", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "926", "SubTopic": "230", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483170/926-230-45-1" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.15(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.17)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "210", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03.7(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480981/942-825-50-1" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "985", "SubTopic": "20", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//205/tableOfContent" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 201.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-11" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.1,2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2(a),(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7(c),9(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.8)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//235/tableOfContent" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//275/tableOfContent" }, "r144": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//360/tableOfContent" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.CC)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480091/360-10-S99-2" }, "r148": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//440/tableOfContent" }, "r149": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//470/tableOfContent" }, "r150": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481284/470-20-25-10" }, "r151": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-5" }, "r152": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//505/tableOfContent" }, "r153": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r154": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "4", "Subparagraph": "(SAB Topic 4.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-4" }, "r155": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 4.F)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-5" }, "r156": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r157": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r158": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r159": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Paragraph": "9", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r160": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r161": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r162": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r163": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r164": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r165": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r166": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r167": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r168": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r169": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r170": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(13)(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r171": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r172": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r173": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.13(h))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r174": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04.9)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r175": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11B", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-11B" }, "r176": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-15" }, "r177": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "10", "Topic": "310", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-6" }, "r178": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "840", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481440/840-10-50-1" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "210", "Topic": "946", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-20" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "270", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-6" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-1" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-6" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480321/958-360-50-7" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02.22(a)(2))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "808", "Publisher": "FASB", "URI": "https://asc.fasb.org//808/tableOfContent" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(a)", "Publisher": "SEC" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "(b)", "Subparagraph": "(1)", "Publisher": "SEC" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "a", "Publisher": "SEC" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "2", "Publisher": "SEC" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Footnote": "4", "Publisher": "SEC" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column B", "Publisher": "SEC" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column C", "Publisher": "SEC" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column D", "Publisher": "SEC" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column E", "Publisher": "SEC" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column F", "Publisher": "SEC" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column G", "Publisher": "SEC" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column H", "Publisher": "SEC" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "28", "Paragraph": "Column I", "Publisher": "SEC" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "29", "Footnote": "4", "Publisher": "SEC" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483489/210-10-50-1" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(3)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(210.5-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-5" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-17" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-2" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(k)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//260/tableOfContent" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-11" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-16" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-3" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482964/270-10-50-6A" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482987/272-10-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-25" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-9" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481962/310-10-50-4" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481569/310-20-50-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481664/323-10-45-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-13" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479319/326-20-50-3D" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//330/tableOfContent" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-1" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "330", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483080/330-10-50-4" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482598/350-20-45-2" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482573/350-20-50-2" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482665/350-30-50-2" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1C" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1E" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1F" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1I" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-6" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-1" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479837/606-10-45-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-4" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-8" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "712", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//712/tableOfContent" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(n)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//718/tableOfContent" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-1D" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-3" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "15", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483044/730-10-05-1" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//740/tableOfContent" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-25" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-28" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482525/740-10-45-6" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-19" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-2" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-20" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB TOPIC 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479581/805-30-50-4" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "808", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479402/808-10-50-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//830/tableOfContent" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481839/830-10-45-17" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482014/830-20-35-1" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481956/830-20-45-1" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481926/830-20-50-1" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483013/835-20-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482900/835-30-50-1" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//842-20/tableOfContent" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-7" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-4" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479773/842-30-50-5" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479741/842-40-50-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//850/tableOfContent" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-6" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481435/852-10-45-14" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//855/tableOfContent" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482312/912-310-45-11" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "912", "SubTopic": "330", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482105/912-330-50-1" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483154/926-20-50-5" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483147/928-340-50-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "33", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "35A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r578": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(3)(d)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1" }, "r583": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2" }, "r590": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r591": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-2" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-5" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-6" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-3" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-21" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(5)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r654": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r655": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r656": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r657": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r658": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r659": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r660": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r661": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r662": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r663": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r664": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r665": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1" }, "r666": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r667": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r668": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r669": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r670": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r671": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r672": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r673": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2" }, "r674": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r675": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r676": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r677": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-3" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479851/948-310-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "450", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480598/954-450-50-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r701": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479438/970-360-S99-1" }, "r702": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1" }, "r703": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1" }, "r704": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r705": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-13H" }, "r706": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1" }, "r707": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-8" }, "r708": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r709": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4" }, "r710": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52" }, "r711": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30" }, "r712": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31" }, "r713": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A" }, "r714": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482548/350-20-55-24" }, "r715": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r716": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B" }, "r717": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C" }, "r718": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69E" }, "r719": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69F" }, "r720": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13" }, "r721": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r722": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8" }, "r723": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r724": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4J" }, "r725": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481175/810-10-55-4K" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "53", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F" }, "r729": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1" }, "r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" }, "r735": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10" }, "r738": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r741": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r742": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-3" }, "r743": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-11" }, "r744": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r745": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "321", "Publisher": "FASB", "URI": "https://asc.fasb.org//321/tableOfContent" }, "r746": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Topic": "325", "Publisher": "FASB", "URI": "https://asc.fasb.org//325/tableOfContent" }, "r747": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "12", "Subsection": "04", "Paragraph": "(a)", "Publisher": "SEC" }, "r748": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(i)", "Publisher": "SEC" }, "r749": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "01", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r750": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-X (SX)", "Number": "210", "Section": "13", "Subsection": "02", "Paragraph": "(a)", "Subparagraph": "(4)(iv)", "Publisher": "SEC" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483504/205-10-50-1" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-3" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481990/310-10-45-13" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//320/tableOfContent" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479536/321-10-50-4" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479344/326-20-45-1" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.A)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480341/340-10-S99-1" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org//450/tableOfContent" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479806/606-10-50-5" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479777/606-10-55-91" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-6" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-9" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480123/805-50-15-3" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-4" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-3" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-2" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(15)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479432/944-30-50-2B" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2" } } }